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Summary 
Introduction 
Health Problem 
In the scope of this assessment, chronic low back pain deriving from the fac-
et or sacroiliac joints is the condition of interest. Low back pain is defined as 
pain and discomfort, localised between the costal margin and above the infe-
rior gluteal folds, with or without referred leg pain that persists for at least 
12 weeks. The cause for sacroiliac pain is a sacroiliac joint dysfunction (due 
to hypermobility/instability or hypomobility/fixation). 
The lifetime prevalence of low back pain has been estimated up to 84%. With-
in 12 months, a quarter of the Austrian population is affected by chronic low 
back pain/problems (2014). Reliable epidemiological data on the proportion 
of facet or sacroiliac joint pain is missing. 
Description of Technology 
Radiofrequency denervation (RFD) is a minimally invasive procedure. A ra-
diofrequency generator produces an alternating electrical current through an 
insulated needle. At the tip of the needle, the electric field induces ionic move-
ments in the tissue directly surrounding the tip. The heat from the tip of the 
device is used to produce a lesion in the nerves suspected of contributing to 
the pain. 
Research question 
Is radiofrequency denervation of the facet joints or sacroiliac joint in compar-
ison to placebo or other treatments in patients with chronic facet joint pain or 
sacroiliac joint pain with a positive response to diagnostic block more effec-
tive and safe concerning pain, functional status, global improvement, health-
related quality of life, and complications? 
 
Methods 
Domain effectiveness and safety 
During the scoping process, we identified a recently published Cochrane Re-
view dealing with radiofrequency denervation for chronic low back pain. The 
Cochrane review’s literature search (from inception to May 2014) had been 
conducted in several databases. We decided to use the relevant parts of the 
Cochrane review (on facet and sacroiliac joint pain) as the primary source for 
this report and refrained from conducting a (redundant) systematic literature 
search by ourselves. To ensure completeness and up-to-dateness, we performed 
the following manual searches: contact with the Cochrane Review fist author, 
systematic search in Medline using the search strategy from the Cochrane re-
view (complemented by the search term sacroiliac joint), hand-search in Pub-
med, and contact of two manufacturers. 
 
 
chronische  
Rückenschmerzen 
können ihren Ausgang 
u. a. von Facetten- oder 
den Iliosakralgelenken 
nehmen 
Lebenszeitprävalenz  
von Rückenschmerzen 
bis zu 84 % 
Radiofrequenz-
denervierung (RFD)  
ist minimal invasive 
Methode, die durch 
Wärmeentwicklung 
gezielt schmerzleitende 
Nerven zerstört 
Frage, ob RFD andere 
Interventionen 
überlegen 
rezenter Cochrane 
Review identifiziert, 
ergänzt um: 
Kontaktaufnahme mit 
Cochrane Erstautor, 
(systematisches Update) 
Medline Suche ergänzt 
um den spezifischen 
Begriff der 
Iliosakralgelenke 
Gelenke, Handsuche  
in Pubmed 
Radiofrequency denervation for sacroiliac and facet joint pain 
8 LBI-HTA | 2016 
Results 
Available evidence 
10 RCTs for facet joint pain and 2 RCTs for sacroiliac joint pain fulfilled the 
inclusion criteria for the effectiveness assessment. Further, 3 RCTs (compar-
ing different RFD methods) were included for safety considerations. 
6 of 10 facet joint pain RCTs were placebo controlled (Sham intervention), 4 
used steroid injections as comparator. The studies were published between 
1994 and 2014, and included 31-120 patients each (a total of 323 patients in 
the placebo-controlled and 356 in the steroid injection controlled trials). In-
clusion criteria differed considerably between studies, e.g., patients had to suf-
fer from back pain for more than 3 months up to at least 2 years prior to the 
intervention. The mean age of included patients ranged from 41 to 64 years. 
The percentage of female participants was more than 55% in all but one tri-
al. Patient follow up ranged from 3 to 12 months. Loss to follow up ranged 
from 0% to 10%, 2 trials did not report drop-outs. Half of the trials have been 
judged to have a high risk of bias, e.g., due to unclear blinding, unclear or high 
number of drop-outs, or differing baseline characteristics. 
Both RCTs evaluating radiofrequency denervation for sacroiliac joint pain 
were placebo controlled, published from 2008-2012 and included a total of 
79 patients. Patients had to suffer from low back pain at least for 6 months. 
The mean age of patients was 52-64 years, 57-82% of the patients were female. 
Length of follow-up was up to 9 months, but patients of the control groups 
were given the opportunity to cross-over after 1-3 months. One RCT was judged 
to have a low risk of bias, whereas the second RCT might imply a high risk 
due to differing baseline characteristics.  
Clinical effectiveness 
Overall, the strength of evidence for the effectiveness of radiofrequency de-
nervation for facet joint pain in comparison to placebo (sham intervention) 
is low. RFD compared to placebo might reduce pain in the short term (≤1 
month), but not in the intermediate term (>1 to 12 months); it might not in-
crease functional status <6 months, but between 6 to 12 months; it might not 
improve quality of life at 3 months, but might lead to a global improvement 
in the intermediate term (>1 up to 6 months).  
Overall, the strength of evidence for the effectiveness of radiofrequency de-
nervation for facet joint pain in comparison to steroid injections is low to very 
low. RFD compared to steroid injections might reduce pain up to 12 months 
post intervention; it might not improve the functional status in the interme-
diate term (≥6 to <12 months); it might not improve quality of life up to 12 
months. For the outcome of global improvement, no evidence is available. 
Overall, the strength of evidence for the effectiveness of radiofrequency de-
nervation for sacroiliac joint pain in comparison to placebo (sham inter-
vention) is low to very low. RFD compared to placebo might not reduce pain 
or improve functional status in the short term (≤1 month), but thereafter up 
to 3 months; it might lead to a global improvement up to 3 months; it might 
not increase quality of life up to 1, but up to 3 months. No evidence is avail-
able for all critical outcomes in an observation period of >3 months. 
15 RCTs 
für Facettengelenke: 
6 Plazebo/4 Steroid-
injektionstherapie 
kontrolliert;  
~680 PatienInnen,  
max. Beobachtungsdauer 
12 Monate, 
die Hälfte der Studien 
mit hohem Biasrisiko 
für Iliosakralgelenke: 
2 Plazebo kontrolliert;  
~80 PatienInnen,  
max. Beobachtungsdauer 
3 Monate, 
1 Studie mit hohem/ 
1 mit geringem Biasrisiko 
Facettengelenks-RFD  
vs. Plazebo insgesamt 
geringe Evidenz  
(z. B. für kurzfristige 
Schmerzlinderung  
<1 Monat) 
Facettengelenks-RFD  
vs. Steroidinjektion 
insgesamt (sehr) 
geringe Evidenz (z. B. 
für Schmerzlinderung 
bis zu 12 Monate) 
RFD im Bereich der 
Iliosakralgelenke vs. 
Plazebo insgesamt 
(sehr) geringe Evidenz 
(z. B. für  
Schmerzlinderung  
>1 bis ≤3 Monate) 
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Safety 
There is very low evidence that 
 facet-joint RFD compared to placebo might not increase complications. 
 facet-joint RFD compared to steroid injections does not lead to com-
plications/major adverse events, infections or motor or sensory deficits, 
but might cause superficial burns after the intervention and an initial 
increase in back pain. 
 sacroiliac-joint RFD compared to placebo might not increase serious 
complications. 
 in the comparison of different RFD techniques, no complications/major 
adverse events, but mild localised pain or neuropathy like pain, can 
be observed. 
Upcoming evidence 
We identified 2 ongoing RCTs on lumbar facet joint pain comparing con-
ventional and cooled RFD (NCT02478437) and RFD with 80 vs. 90°C (NCT-
02148003), and 2 on sacroiliac joint pain that compare RFD vs. a sham in-
tervention (NCT01726608) or two different RFD methods (NCT02382289). 
Reimbursement 
Currently, seven RF lesion probe devices (not ‘back-pain specific’) are ap-
proved by the Food and Drug Administration (FDA). The cooled RFD sys-
tem, which had been used in sacroiliac joint RFD studies so far, received FDA 
clearance and CE Marking. In Austria, radiofrequency denervation of the fac-
et and sacroiliac joints can be reimbursed via the Austrian DRG-system (Leis-
tungsorientierte Krankenanstaltenfinanzierung/LKF) using the code AJ140 
“percutaneous destruction of peripheral nerves”. 
 
Discussion 
Overall, the level of evidence for the estimated effects is very low to low. This 
conclusion is primarily based on the high risk of bias of the majority of in-
cluded studies (especially the potential effects of non-blinding of patients on 
exclusively patient-reported outcomes) and the small sample sizes. 
For reliable statements on effectiveness, long-term data (based on e.g., regis-
tries) would be essential, to determine the mean period of the effect, which 
is assumed to be not permanent due to nerve recovery, as well as alternative 
(more invasive) therapies prevented (e.g, SI joint fusion).  
Different RFD techniques were used in the included trials (cooled RFD for 
sacroiliac joint pain and conventional or pulsed RFD methods for facet joint 
pain). Due to the observed heterogeneity (temperature, duration) and the cur-
rent research focus (comparison of different techniques), it seems that the op-
timal “dose” of RFD is still under examination. In addition, the patient pop-
ulation varied between studies (different levels of ‘chronicity’), which could 
have had an impact on the study results. 
Results from facet joint RFD studies cannot be adopted one-to-one to SI joint 
RFD. Differences between medial and lateral branch neurotomy result from 
differences in the sensory innervation. Variations in the sacroiliac joint in-
nervation are addressed by a different RFD technique that aims at causing 
‘bigger’ (and more) lesions than used in conventional facet joint RFD. 
sehr geringe Evidenz  
für „keine 
schwerwiegenden 
Komplikationen” 
3 von 4 laufenden  
RCTs vergleichen 
unterschiedliche  
RFD Methoden 
diverse RFD Devices 
‘FDA approved’ bzw.  
CE-zertifiziert 
 
Abrechnung aktuell  
in Ö über Code AJ140 
insgesamt basieren die 
Effektschätzer auf einem 
geringen Evidenzlevel 
(v. a. durch Biasrisiko 
und geringe 
Stichprobengröße)  
Übertragbarkeit der 
Ergebnisse potenziell 
eingeschränkt durch 
Unterschiede in den 
verwendeten RFD 
Methoden und 
eingeschlossenen Pat. 
Ergebnisse der 
Facettengelenks-RFD 
nicht 1:1 auf 
Iliosakralgelenks-RFD 
übertragbar 
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Patients with joint pain due to acute trauma, fracture, malignancy, and in-
flammatory disease were excluded from this review. Therefore, no conclusions 
can be drawn on the effectiveness of RFD in these indications.  
Neither for RFD in facet joints nor for RFD in sacroiliac joints (SI) are the 
long-term data (>12 months) available. Due to crossover, the situation is worst 
for RFD in SI joints, for which no group comparisons >3 months exist.  
Limitations of our work comprise the bare confidence that the Cochrane Re-
view’s authors have not missed relevant trials, our safety assessment is only 
based on RCTs and some of the meta-analyses are insufficiently sound due 
to study dependencies or small number of studies.  
 
Conclusion 
The current evidence is not sufficient to prove that the assessed technology 
radiofrequency denervation [in adult patients with chronic (>3 months, facet 
joint- or sacroiliac joint) low back pain who had a positive response to diag-
nostic block] is more effective than, and as safe as, the comparator(s) (place-
bo/sham intervention or conventional treatment). New study results will in-
fluence the estimated effect considerably. The re-evaluation is recommended 
in 2019. 
  
Identifizierte 
Evidenzlücken v. a. 
keine Langzeitergebnisse  
derzeit keine 
Empfehlung zur 
Aufnahme in den 
Leistungskatalog 
Zusammenfassung 
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Zusammenfassung 
Einleitung 
Indikation und therapeutisches Ziel 
Im Fokus dieses Berichts stehen PatientInnen mit chronischen Rückenschmer-
zen, die von den Facettengelenken oder den Iliosakralgelenken ausgehen. 
(Chronische) Schmerzen im Bereich des „unteren Rückens“ (Lumbalgien) 
sind Schmerzen zwischen Rippenbogen und Gesäßfalten, die in das entspre-
chende Bein ausstrahlen können, und für mindestens 12 Wochen bestehen. 
Schmerzen aus dem Bereich der Iliosakralgelenke sind durch eine Gelenks-
funktionsstörung bedingt (Hypermobilität/Instabilität bzw. Hypomobilität/ 
Fixierung). 
Die Lebenszeitprävalenz von Rückenschmerzen beträgt bis zu 84 %. Inner-
halb von 12 Monaten gibt ein Viertel der Österreichischen Bevölkerung an, 
von chronischen Rückenschmerzen/-problemen betroffen gewesen zu sein 
(2014). Verlässliche epidemiologische Daten zum Anteil von Facetten- bzw. 
Iliosakralgelenksschmerzen fehlen.  
Beschreibung der Technologie 
Radiofrequenzdenervierung (RFD) ist eine minimal invasive Behandlungs-
methode. Ein Radiofrequenzgenerator erzeugt Wechselstrom. Das elektrische 
Feld induziert an der Spitze einer isolierten Nadel Ionenbewegungen im um-
gebenden Gewebe. Diese Wärme wird verwendet, um eine Läsion (Verletzung) 
jenes Nervens hervorzurufen, welcher als Verursacher der Schmerzweiterlei-
tung vermutet wird. 
Forschungsfrage 
Ist die Radiofrequenzdenervierung im Bereich der Facetten- bzw. Iliosakral-
gelenke im Vergleich zu Plazebo(Schein-)interventionen oder anderen Be-
handlungsmethoden bei PatientInnen mit chronischen Facetten- oder Iliosa-
kralgelenksschmerzen (mit positivem Ansprechen auf eine diagnostische Ner-
venblockade) im Hinblick auf Schmerzen, Funktionalität, Allgemeine Ver-
besserung, gesundheitsbezogene Lebensqualität und Komplikationen wirksa-
mer und sicherer? 
 
Methoden 
Klinische Wirksamkeit und Sicherheit 
Während des Scopingprozesses identifizierten wir einen rezenten Cochrane 
Review zur Radiofrequenzdenervierung bei chronischen Rückenschmerzen. 
Die systematische Literatursuche war in mehrere Literaturdatenbaken (bis 
Mai 2014) durchgeführt worden. Wir entschieden, die relevanten Berichts-
teile dieser Übersichtsarbeit (zu Facetten- und Iliosakralgelenken) als Grund-
lage für den vorliegenden Bericht zu verwenden und verzichteten auf eine ei-
gene (redundante) systematische Literatursuche. Um die Vollständigkeit und 
Aktualität zu gewährleisten führten wir zusätzlich folgende Handsuchen durch: 
Kontaktaufnahme mit dem Erstautor des Cochrane Reviews, systematische 
Suche in Medline unter Verwendung der Suchstrategie des Cochrane Reviews 
(ergänzt um den Suchbegriff ‚sacroiliac joint’), manuelle Suche in PubMed 
und Kontaktierung zweier Hersteller. 
chronische  
Rückenschmerzen 
können ihren Ausgang 
u. a. von Facetten- oder 
den Iliosakralgelenken 
nehmen 
Lebenszeitprävalenz  
von Rückenschmerzen 
bis zu 84 % 
Radiofrequenz-
denervierung (RFD)  
ist minimal invasive 
Methode, die durch 
Wärmeentwicklung 
gezielt schmerzleitende 
Nerven zerstört 
Frage, ob RFD andere 
Interventionen 
überlegen 
rezenter Cochrane 
Review identifiziert, 
ergänzt um: 
Kontaktaufnahme mit 
Cochrane Erstautor, 
(systematisches 
Update) Medline Suche 
ergänzt um den 
spezifischen Begriff  
der Iliosakralgelenke 
Gelenke, Handsuche  
in PubMed 
Radiofrequency denervation for sacroiliac and facet joint pain 
12 LBI-HTA | 2016 
Ergebnisse 
Verfügbare Evidenz 
10 randomisiert kontrollierte Studien (RCTs) zu Facettengelenksschmerzen 
und 2 RCTs zu Iliosakralgelenksschmerzen erfüllten die Einschlusskriterien 
für die Wirksamkeitsanalyse. Weitere 3 RCTS (Vergleiche unterschiedlicher 
RFD Methoden) wurden für die Sicherheitsbeurteilung eingeschlossen.  
6 der 10 Facettengelenksschmerz-RCTs waren Plazebo-kontrolliert (Schein-
intervention), 4 verwendeten Steroidinjektionen als Kontrollintervention. Die 
Studien wurden zwischen 1994 und 2014 publiziert und inkludierten jeweils 
31-120 PatientInnen (gesamt 323 Patientinnen in den Plazebo-kontrollierten 
und 356 in den Steroidinjektions-kontrollierten Studien). Die Einschlusskri-
terien unterschieden sich beträchtlich zwischen den Studien: PatientInnen 
mussten beispielsweise mehr als 3 Monate bis zu mindestens 2 Jahre an Rü-
ckenschmerzen leiden. Das mittlere Alter eingeschlossener PatientInnen reich-
te von 41 bis 64 Jahren. Der Anteil weiblicher StudienteilnehmerInnen be-
trug mit Ausnahme einer Studie mehr als 55 %. Die Nachbeobachtungszeit 
reichte von 3 bis 12 Monaten, zu 0-10 % der PatientInnen lagen zu diesem 
Zeitpunkt keine Daten vor (2 Studien machten keine Angaben hierzu). Die 
Hälfte der Studien weist ein Hohes Biasrisiko auf, beispielsweise aufgrund 
unklarer Verblindung, unklarer oder hoher Anzahl an Drop-outs oder Grup-
penunterschieden in den Basischarakteristika. 
Die beiden RCTs zu RFD bei Iliosakralgelenksschmerzen waren Plazebo-
kontrolliert, wurden 2008-2012 publiziert und schlossen insgesamt 79 Pati-
entInnen ein. PatientInnen mussten zuvor mindestens 6 Monate an Rücken-
schmerzen gelitten haben. Das mittlere Alter der PatientInnen war 52-64 Jah-
re, 57-82 % der PatientInnen waren weiblich. Die Nachbeobachtungsdauer be-
trug 9 Monate, allerdings hatten die PatientInnen der Kontrollgruppe nach 
1-3 Monaten die Möglichkeit, in die Interventionsgruppe zu wechseln. Ein 
RCT wies ein geringes, das zweite ein hohes Biasrisiko (aufgrund von Grup-
penunterschieden in den Basischarakteristika) auf.  
Klinische Wirksamkeit 
Insgesamt ist die Stärke der Evidenz für die Wirksamkeit der RFD bei Fa-
cettengelenksschmerzen im Vergleich zu einer Plazebointervention gering. 
Die RFD könnte im Plazebovergleich zu einer kurzfristigen (≤1 Monat), 
nicht jedoch mittelfristigen (>1 bis 12 Monate) Schmerzreduktion führen, 
die Funktionalität nicht im Zeitraum < 6 Monaten, jedoch zwischen 6 und 
12 Monaten verbessern, keinen Einfluss auf die gesundheitsbezogene Lebens-
qualität nach 3 Monaten haben, aber zu einer mittelfristigen (>1 bis zu 6 
Monate) allgemeinen Verbesserung führen.  
Insgesamt ist die Stärke der Evidenz für die Wirksamkeit der RFD bei Fa-
cettengelenksschmerzen im Vergleich zur Steroidinjektion gering bis sehr 
gering. Die RFD könnte im Steroidinjektionsvergleich zu einer Schmerzre-
duktion bis zu 12 Monate postinterventionell führen, die Funktionalität mit-
telfristig (≥6 bis <12 Monate), und die gesundheitsbezogene Lebensqualität 
im Beobachtungszeitraum von 12 Monaten jedoch nicht verbessern. Für Aus-
wirkungen auf die allgemeine Verbesserung ist keine Evidenz verfügbar.  
15 RCTs 
für Facettengelenke: 
6 Plazebo-/4 Steroid-
injektionstherapie 
kontrolliert;  
~680 PatienInnen,  
max. Beobachtungsdauer 
12 Monate, 
die Hälfte der Studien 
mit hohem Biasrisiko 
für Iliosakralgelenke: 
2 Plazebo kontrolliert;  
~80 PatienInnen,  
max. Beobachtungsdauer 
3 Monate, 
1 Studie mit hohem/ 
1 mit geringem Biasrisiko 
Facettengelenks-RFD  
vs. Plazebo insgesamt 
geringe Evidenz  
(z. B. für kurzfristige 
Schmerzlinderung  
<1 Monat) 
Facettengelenks-RFD  
vs. Steroidinjektion 
insgesamt (sehr) 
geringe Evidenz (z. B. 
für Schmerzlinderung 
bis zu 12 Monate) 
Zusammenfassung 
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Insgesamt ist die Stärke der Evidenz für die Wirksamkeit der RFD bei Ilio-
sakralgelenksschmerzen im Vergleich zu einer Plazebointervention gering 
bis sehr gering. Die RFD konnte kurzfristig (≤1 Monat) Schmerzen nicht 
reduzieren sowie die Funktionalität oder Lebensqualität nicht verbessern (je-
doch >1 bis zu 3 Monate) und führte zu einer allgemeinen Verbesserung bis 
zu 3 Monate. Für den Beobachtungszeitraum >3 Monate fehlt jegliche Evi-
denz zu den o.g. Ergebnisparametern.  
Sicherheit 
Es ist sehr geringe Evidenz verfügbar, dass  
 die RFD im Bereich der Facettengelenke im Plazebovergleich nicht 
mit mehr Komplikationen assoziiert ist. 
 die RFD im Bereich der Facettengelenke im Vergleich mit Steroid-
injektionen nicht zu mehr Komplikationen/schwerwiegenden uner-
wünschten Ereignissen, Infektionen oder motorischen bzw. sensori-
schen Defiziten führt, aber zu oberflächlichem Brennen nach er In-
tervention sowie initialer Verschlechterung der Rückenschmerzsymp-
tomatik. 
 die RFD im Bereich der Iliosakralgelenke im Plazebovergleich nicht 
zu mehr schwerwiegenden Komplikationen führt  
 im Vergleich verschiedener RFD Techniken keine Komplikationen/ 
schwerwiegende unerwünschte Ereignisse beobachtet wurden, jedoch 
geringfügige lokalisierte bzw. Neuropathie-ähnliche Schmerzen.  
Laufende Studien 
Wir identifizierten 2 laufende RCTs, welche unterschiedliche RFD Techni-
ken (NCT02478437: konventionelle vs. ‚cooled’ RFD; NCT02148003: RFD 
mit 80 vs. 90°C) bei lumbalen Facettengelenksschmerzen vergleichen sowie 
2 RCTs zu RFD bei Schmerzen im Bereich der Iliosakralgelenke (NCT-
01726608: RFD vs. Plazebo; NCT02382289: Vergleich zweier RFD Techni-
ken). 
Kostenerstattung 
Derzeit sind sieben RFD Systeme (nicht Rückenschmerz-spezifisch) von der 
US Amerikanischen Food and Drug Administration (FDA) zugelassen. Das 
‘cooled RFD-’System, welches in den Studien zu den Iliosakralschmerzen 
verwendet wurde, besitzt sowohl eine FDA Zulassung als auch eine CE Zerti-
fizierung. In Österreich kann die RFD der Facetten- oder Iliosakralgelenke 
derzeit über den (unspezifischen) Code AJ140 („perkutane Destruktion peri-
pherer Nerven“) des Leistungskatalogs für die leistungsorientierte Kranken-
anstaltenfinanzierung abgerechnet werden.  
 
Diskussion 
Insgesamt basieren die Effektschätzer auf einem geringen bis sehr geringen 
Evidenzlevel. Diese Schlussfolgerung basiert primär auf dem hohen Biasri-
siko des Großteils der inkludierten Studien (v. a. die potenziellen Auswirkun-
gen der nicht-Verblindung von PatientInnen auf ausschließlich Patientinnen-
berichtete Ergebnisparameter) und die geringen Stichprobenumfänge. 
Für belastbare Aussagen zur Wirksamkeit wären Langzeitdaten (z. B. auf Re-
gistern basierend) erforderlich, um die mittlere Wirkungsdauer zu bestim-
RFD im Bereich der 
Iliosakralgelenke vs. 
Plazebo insgesamt 
(sehr) geringe Evidenz 
(z. B. für  
Schmerzlinderung  
>1 bis <=3 Monate) 
sehr geringe Evidenz für 
„keine schwerwiegenden 
Komplikationen” 
3 von 4 laufenden RCTs 
vergleichen 
unterschiedliche  
RFD Methoden 
diverse RFD Devices 
‘FDA approved’ bzw.  
CE-zertifiziert 
 
Abrechnung aktuell  
in Ö über Code AJ140 
insgesamt basieren  
die Effektschätzer  
auf einem geringen 
Evidenzlevel (v. a. durch 
Biasrisiko und geringe 
Stichprobengröße)  
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men, welche aufgrund der Nervenregeneration als nicht permanent angenom-
men wird, sowie um bestimmen zu können, ob/welche alternativen (invasi-
veren) Behandlungen verhindert werden können (z. B. die Fusion des Iliosa-
kralgelenks).  
In den eingeschlossenen Studien wurden unterschiedliche RFD Techniken 
(‘cooled’ RFD für Iliosakralgelenksschmerzen und konventionelle oder ge-
pulste RFD Methoden für Facettengelenksschmerzen). Aufgrund der beo-
bachteten Heterogenität (Temperatur, Dauer) und dem aktuellen Forschungs-
fokus (Vergleich unterschiedlicher RFD Techniken) scheint die ‚optimale Do-
sis’ der RFD nach wie vor beforscht zu werden. Darüber hinaus unterschied 
sich die PatientInnenpopulation zwischen den Studien (Unterschiedliches Aus-
maß der Chronizität der Schmerzen), was einen Einfluss auf die Studiener-
gebnisse haben könnte.  
Die Ergebnisse der Facettengelenks-RFD können nicht eins zu eins auf die 
Anwendung der RFD bei Iliosakralgelenksschmerzen übertragen werden. Die 
Unterschiede zwischen der medialen und lateralen Neurotomie basieren auf 
Unterschieden in der Gelenks-Innervation. Die anatomischen Variationen im 
Bereich der Iliosakralgelenke werden durch eine spezielle RFD Technik ad-
ressiert, welche darauf abzielt größere (und auch mehr) Läsionen hervorzu-
rufen als die konventionelle Technik. 
PatientInnen mit Gelenksschmerzen aufgrund von Traumata, Frakturen, ma-
lignen oder entzündlichen Erkrankungen wurden von diesem Bericht ausge-
schlossen. Daher können keine Aussagen zur Wirksamkeit der RFD bei die-
sen PatientInnenpopulationen getroffen werden. 
Weder für die RFD im Bereich der Facettengelenke, noch für jene im Be-
reich der Iliosakralgelenke sind Langzeitdaten (>12 Monate) verfügbar. Auf-
grund des Cross-overs (der Möglichkeit aus der Plazebo- in die Interventi-
onsgruppe zu wechseln) ist die Situation am schlechtesten für die RFD im 
Bereich der Iliosakralgelenke, für welche keine Gruppenvergleiche (RFD vs. 
Plazebo) nach mehr als 3 Monaten vorliegen. 
Als Limitationen unserer Arbeite können folgende Faktoren betrachtet wer-
den: unser Vertrauen, dass die AutorInnen des Cochrane Reviews keine re-
levanten Studien übersehen hatten, die Basierung unserer Sicherheitsanaly-
se ausschließlich auf RCTs und die teilweise beschränkte Aussagekraft der 
Metaanalysen (aufgrund von geringer Studienanzahl bzw. voneinander ab-
hängigen Studienergebnissen).  
 
Empfehlung  
Die aktuelle Evidenz ist nicht ausreichend zu belegen, dass die untersuchte 
Technologie Radiofrequenzdenervierung [bei erwachsenen PatientInnen mit 
chronischen (>3 Monate, Facetten- oder Iliosakralgelenks-)Rückenschmer-
zen, die auf eine diagnostische Nervenblockade angesprochen hatten] wirk-
samer und vergleichbar sicher als/wie die Kontrollintervention(en) (Plazebo/ 
Scheinintervention oder konservative Behandlung) ist. Neue Studienergeb-
nisse werden den geschätzten Effekt maßgeblich beeinflussen. Eine Reeva-
luierung ist 2019 empfohlen.  
 
Übertragbarkeit der 
Ergebnisse potenziell 
eingeschränkt durch 
Unterschiede in den 
verwendeten RFD 
Methoden und  
eingeschlossenen Pat. 
Ergebnisse der 
Facettengelenks-RFD 
nicht 1:1 auf 
Iliosakralgelenks-RFD 
übertragbar 
Identifizierte 
Evidenzlücken  
v. a. keine 
Langzeitergebnisse  
derzeit keine 
Empfehlung zur 
Aufnahme in den 
Leistungskatalog 
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1 Scope 
1.1 PICO question 
Is radiofrequency denervation of the facet joints or sacroiliac joint in com-
parison to placebo or other treatments in patients with chronic facet joint 
pain or sacroiliac joint pain with a positive response to diagnostic block more 
effective and safe concerning pain, functional status, global improvement, 
health-related quality of life, and complications? 
 
 
1.2 Inclusion criteria 
Inclusion criteria for relevant studies are summarized in Table 1-1. 
Table 1-1: Inclusion criteria 
Population second-line treatment in adult patients with chronic (>3 months) low back pain  
(facet joint pain or sacroiliac joint pain) who had a positive response to diagnostic block  
ICD-10 code: M54.5 low back pain 
MeSH-terms: low back pain, zygapophyseal joint, sacroiliac joint 
Patients with acute trauma, fracture, malignancy and inflammatory disease were excluded. 
Intervention radiofrequency (RF) denervation (synonyms: radiofrequency neurotomy, 
radiofrequency ablation) 
No limits on the temperature were applied. Both continuous and pulsed RF were included. 
Control placebo 
other treatments* 
Outcomes  
Efficacy  pain 
 functional status 
 global improvement 
 health-related quality of life 
 ability to work 
 satisfaction with treatment 
Safety  complications 
Study design randomised controlled trials 
* In deviation from the Cochrane review, studies comparing different methods of RFD were included for safety analysis only 
(not for efficacy).  
 
 
PIKO-Frage 
Einschlusskriterien  
für relevante Studien 
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2 Methods 
2.1 Research questions 
Description of the technology 
Element ID Research question 
B0001 What is radiofrequency denervation? 
B0002 What is the claimed benefit of radiofrequency denervation in relation to the comparators? 
B0004 Who administers radiofrequency denervation and in what context and level of care is it 
provided? 
B0008 What kind of special premises are needed to use radiofrequency denervation? 
B0009 What supplies are needed to use radiofrequency denervation? 
A0020 For which indications has radiofrequency denervation received marketing authorisation or  
CE marking? 
A0021 What is the reimbursement status of radiofrequency denervation? 
 
Health problem and Current Use 
Element ID Research question 
A0001 For which health conditions and for what purposes is radiofrequency ablation/denervation used? 
A0002 What is the disease or health condition in the scope of this assessment? 
A0003 What are the known risk factors for chronic low back pain? 
A0004 What is the natural course of the disease or health condition? 
A0005 What is the burden of disease for patients with chronic low back pain? 
A0006 What are the consequences of chronic low back pain for the society? 
A0024 How is chronic low back pain currently diagnosed according to published guidelines  
and in practice? 
A0025 How is chronic low back pain currently managed according to published guidelines  
and in practice? 
A0007 What is the target population in this assessment?  
A0023 How many people belong to the target population? 
A0011 How much is radiofrequency denervation of the facet and sacroiliac joints utilised? 
 
Clinical Effectiveness 
Element ID Research question 
D0001 What is the expected beneficial effect of radiofrequency denervation on mortality? 
D0005 How does radiofrequency denervation affect symptoms and findings (severity, frequency)  
of chronic low back pain? 
D0006 How does radiofrequency denervation affect progression (or recurrence) of chronic low back pain? 
D0016 How does the use of radiofrequency denervation affect activities of daily living? 
D0012 What is the effect of radiofrequency denervation on generic health-related quality of life? 
D0013 What is the effect of radiofrequency denervation on disease-specific quality of life? 
D0017 Was the use of radiofrequency denervation worthwhile? 
 
 
Radiofrequency denervation for sacroiliac and facet joint pain 
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Safety 
Element ID Research question 
C0008 How safe is the technology in comparison to the comparator(s)? 
C0002 Are there harms related to dosage or frequency of applying the technology? 
C0004 How does the frequency or severity of harms change over time or in different settings? 
C0005 What are the susceptible patient groups that are more likely to be harmed through the  
use of the technology? 
C0007 Are the technology and the comparator(s) associated with user-dependent harms? 
 
 
2.2 Sources 
Description of the technology and Health Problem and current use 
 Publications identified by hand search 
 Questionnaire completed by the submitting hospital  
 
 
2.3 Systematic literature search 
During the scoping process we identified a recently published Cochrane Re-
view [1] dealing with radiofrequency denervation for chronic low back pain. 
This Cochrane review had a broader scope than our assessment (including 
not only pain from facet joints’ and sacroiliac joints, but also from interver-
tebral discs and the dorsal root ganglion). The Cochrane review’s literature 
search (from inception to May 2014) had been conducted in the following 
databases: 
 Cochrane Central Register of Controlled Trials (CENTRAL) 
 MEDLINE 
 MEDLINE In-Process & Other Non-Indexed Citations 
 EMBASE 
 Cumulative Index to Nursing and Allied Health Literature  
(CINAHL) 
 PsycINFO 
 ClinicalTrials.gov 
 World Health Organization (WHO) International Clinical Trials 
Registry Platform (ICTRP) 
The complete search strategies can be found in the Appendix of the Cochrane 
review [1]. Additionally, the review authors mentioned an update of the lit-
erature search in June 2015. 
Therefore, we decided to use the relevant parts of the Cochrane review (deal-
ing with the facet and sacroiliac joints) as primary source for this report and 
we refrained from conducting a (redundant) systematic literature search by 
ourselves.  
Informationen aus 
Handsuche und 
Einreicherangaben für 
Beschreibung des 
Gesundheitsproblems 
und der Technologie 
vorab Identifikation 
eines rezenten  
Cochrane Reviews 
Verzicht auf eigene 
systematische 
Literatursuche 
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2.3.1 Additional searches 
In a first step, we contacted the first author of the Cochrane review via e-mail. 
She informed us that one additional relevant study [2] had been identified by 
the update search of 2015 and not yet been incorporated in the review.  
Additionally, on December 9th 2015, we conducted a (systematic) search in 
Medline and Pubmed using the search strategy from the Cochrane review 
(complemented by the search term sacroiliac joint) without date restrictions. 
This search yielded 9 additional references. None met the inclusion criteria.  
A hand-search in PubMed identified one article [3], which presented 12-month 
follow-up data of a trial [4] already included in the Cochrane Review. How-
ever, the results were not relevant for this review because the patients of the 
control group were unblinded after 3 months and had the opportunity to 
“cross-over” (i.e., almost all of the control patients also received the interven-
tion). The 3-month follow-up data had already been presented in the includ-
ed article (Patel et al. 2012 [4]). 
Manufacturers of two products for sacroiliac joint pain radiofrequency de-
nervation (Halyard Health and Baylis Medical) were contacted on the 21st of 
December, 2015. However, they didn’t respond to our e-mail. 
 
 
2.4 Flow chart of study selection 
The Cochrane review identified a total of 748 records through database and 
reference searching. 36 records were screened in full text and 23 studies ful-
filled the inclusion criteria of the Cochrane review. Of these, 12 RCTs for 
facet joint pain and 2 RCTs for sacroiliac joint pain were relevant for our as-
sessment. 
Through our additional search (see 2.3.1.), we identified further 11 refer-
ences of which 1 additional RCT fulfilled the inclusion criteria. The selec-
tion process is displayed in Figure 2-1.  
dennoch ergänzt um: 
 
Kontaktaufnahme mit 
Cochrane Erstautorin 
 
systematisches Update 
der Medline Suche 
ergänzt um den 
spezifischen Begriff  
der Iliosakralgelenke 
 
Handsuche in Medline 
und Kontaktaufnahme 
mit 2 Herstellern 
Literaturauswahl  
 
im CR ursprünglich  
12 RCTs für Facetten- und 
2 für Iliosakralgelenke 
ergänzt um ein weiteres 
RCT aus Handsuche 
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* for effectiveness: n=12 (facet joint pain: 10; sacroiliac joint pain:2); for safety: additional 3 RCTs for facet joint pain 
Figure 2-1: Flow chart of study selection (PRISMA Flow Diagram) 
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LBI-HTA: 
Additional records identified 
through hand search  
(n=11) 
Records fully screened 
(n=36) 
Studies ongoing and 
therefore excluded 
(n=5) 
Full-text articles  
assessed for eligibility 
(n=31) 
Studies included in the Cochrane review (n=23) 
 disc pain (n=5) 
 radicular chronic low back pain (n=2) 
 radiating chronic low back pain (n=1) 
 chronic low back pain with or without radiation (n=1) 
 facet joint pain (n=12) 
 sacroiliac joint pain (n=2) 
Studies excluded for 
various reasons  
(n=8) 
Cochrane Review 
Studies included in assessment (n=15)* 
 facet joint pain (n=13) 
 sacroiliac joint pain (n=2) 
Records excluded 
(n=10) 
Methods 
LBI-HTA | 2016 21 
2.5 Analysis 
As the scope of the Cochrane review [1] was broader than our research ques-
tion, this report only focuses on its facet and the sacroiliac joint results. We 
checked the data extraction tables of the Cochrane review for accuracy and 
completeness (based on the included primary studies), adapted them to our 
format, extracted them, and added further relevant information from the pri-
mary studies. Data extraction was performed by one author (IR) and con-
trolled by another author (KR). 
We assessed the quality of included primary studies using the Cochrane Risk 
of Bias Tool (see Table A-5).  
 
 
2.6 Synthesis 
For the crucial outcomes pain (VAS) and functional status (ODI), we aimed 
at providing pooled data for effectiveness. We were able to extract some of 
the Cochrane Review’s meta-analyses to our evidence profiles (‘GRADE ta-
bles’) and added own calculations if necessary. For these, we used the R pack-
age “meta”1. Because of heterogeneity, we chose a random effects model for 
all of our calculations. The only exception was the meta-analysis for the ODI 
score at 12 months (RFD vs. placebo), which only included 2 results from 1 
study [5]. These were highly similar and the results remained exactly the 
same, regardless of whether the random or fixed effects model was used (p. 43). 
Meta-analyses are provided as mean differences (MDs) with 95% confidence 
intervals (95% CIs). When necessary, VAS/NRS scores were converted to 
scales ranging from 0 to 10. The Cochrane Review’s authors solved the prob-
lem of missing standard deviations (SDs) by calculating them using reported 
values of the CI (and, if CIs were not available, they used SDs of baseline 
scores, or estimations of SDs based on other studies with the same population, 
treatment and score). We decided, in one case of missing SDs, for the post-
interventional observation data [6] to use the baseline SD (and to additionally 
provide the effect estimates with halved and doubled SD; see footnote p. 43). 
The questions were answered in plain text format with reference to the evi-
dence profiles (see Table 7-1 to Table 7-5). 
 
                                                             
1 Guido Schwarzer (2015). meta: General Package for Meta-Analysis. R package version 
4.3-2., available at http://CRAN.R-project.org/package=meta 
Daten des Cochrane 
Review auf Basis der 
Primärstudien auf 
Korrektheit und 
Vollständigkeit 
überprüft, extrahiert 
und ggfs. ergänzt  
Biasrisiko der  
Primärstudien mit  
dem Cochrane RoB Tool 
beurteilt 
Meta-Analysen  
für Schmerz und 
Funktionalität 
extrahiert bzw. 
durchgeführt  
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3 Description and technical 
characteristics of technology 
Features of the technology and comparators 
B0001 – What is radiofrequency denervation?  
The use of radiofrequency denervation (RFD) for the treatment of back pain 
was first described in the literature in 1975 [7]. Radiofrequency denervation 
is a minimally invasive procedure that is usually performed with local anaes-
thetic and mild sedation. During this outpatient procedure, the patient is po-
sitioned face down and the skin is anaesthetized with a local anesthetic such 
as lidocaine [8]. Before the RFD procedure is done, a (lateral branch or me-
dial branch) nerve block is performed in order to verify that the pain is be-
ing transmitted by those nerves [9].  
RFD is done with the following elements: a radiofrequency generator, cannu-
las with active tips, and a thermocoupler that serves to sense the body tem-
perature and transmit the radiofrequency energy [7]. 
A radiofrequency generator produces an alternating electrical current with a 
frequency of 250 to 500 kHz through an insulated needle. At the tip of the 
needle, the electric field induces ionic movements in the tissue directly sur-
rounding the tip. The heat from the tip of the device is used to produce a small 
lesion in the nerves suspected of contributing to the pain. The heat causes 
ionic agitation and friction, resulting in protein denaturating, cellular mem-
brane disruptions, increased membrane permeability, and finally, tissue ne-
crosis or lysis. The technique aims to interrupt the pain signals to the brain 
in order to eliminate the pain [1, 7, 10]. 
RFD procedures can be classified in low-intensity RFD (which is adminis-
tered constantly for 60-90 seconds at a specific temperature), cooled RFD 
(which involves the use of a cannula needle that has saline running through 
it to cool the tip), and pulsed RFD (which is done with signal interruption 
every half second, creating temperatures of 42° C) [7].  
Comparators include therapeutic intra-articular (steroid) injections or sham 
RFD. In the sham surgery, a radiofrequency needle is inserted to the same lo-
cation as in RFD, but the electric current is not turned on [8]. 
Synonyms for radiofrequency denervation are the terms radiofrequency ab-
lation and radiofrequency neurotomy.  
B0002 – What is the claimed benefit of radiofrequency denervation  
in relation to the comparators? 
When the joint is determined to be the source of pain, as indicated by a posi-
tive diagnostic nerve block, prolonged pain relief may be achieved by RFD 
with destruction of the nerves to the affected joint. The procedure does not 
cure the source of pain, but instead destroys the pain signal to the brain by 
damaging the nerve, which can result in pain relief lasting from 6 months to, 
occasionally, greater than 12 months [8]. After this period of time, however, 
the nerve will regenerate and the pain may return [9]. 
According to the information provided by the submitting hospital, radiofre-
quency denervation of the sacroiliac joints may maintain the mobility of the 
sacroiliac joint, in comparison to the alternative of sacroiliac joint fusion. 
RFD ist  
minimal-invasive 
Intervention, die  
unter Lokalanästhesie 
durchgeführt wird 
es bedarf 
unterschiedlicher 
Komponenten 
Generator produziert 
Wechselstrom,  
welcher Gewebe in 
Nadelspitzenumgebung 
erwärmt und damit den 
Nerv gezielt schädigt 
unterschiedliche  
RFD Techniken 
verfügbar 
Vergleiche der RFD mit 
Steroidinjektionen oder 
Scheinoperation  
Synonyme auch  
RF-Ablation oder 
Neurotomie 
RFD behebt nicht 
Schmerzursache, 
sondern soll  
Schmerzweiterleitung 
unterbrechen;  
Effekt durch Nerven-
regeneration temporär 
RFD könnte ev. 
erforderliche 
therapeutische Fusion 
des SI Gelenks verhindern  
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Administration, Investments, personnel and tools  
required to use the technology and the comparator(s) 
B0004 – Who administers radiofrequency denervation and  
in what context and level of care is it provided?  
B0008 – What kind of special premises are needed to use radiofrequency 
denervation?  
B0009 – What supplies are needed to use radiofrequency denervation? 
According to the information received by the submitting hospital, the inter-
vention is performed in specialised centres. 
The intervention is performed by an experienced operation team, including 
an experienced orthopaedist, an assistant physician, a nurse, an anaesthetist 
(in the case of sedoanalgesia), and a radiological assistant for intraoperative 
X-ray monitoring.  
An operating room with intraoperative X-ray monitoring is needed for the 
intervention.  
 
Regulatory & reimbursement status  
A0020 – For which indications has radiofrequency denervation  
received marketing authorisation or CE marking? 
RFD for back pain is a procedure and is therefore not subject to regulation by 
the Food and Drug Administration (FDA). However, the FDA regulates RFD 
devices and hence, there are various devices listed in the FDA 510(k) Pre-
market Notification database. The following generators received FDA clear-
ance within the past 5 years: 
 Erase Pen and Erase Tip System for Nerve Ablation, Models  
HC-0O01 and CS-0001 (Cheng Medical Corp.; approved 2011), 
 NT 2000 Lesioning Generator (Neurotherm Inc.; approved 2011), 
 Diros OWL™ URF-3AP(ML) (Diros Technology Inc.; approved 2010), 
 Cosman G4 Radiofrequency Generator (Cosman Medical Inc.;  
approved 2008) [11]. 
There are currently seven RF lesion probe devices approved by the FDA: 
 Baylis Pain Management Probe (Baylis Medical Co., Ontario,  
Canada; approved 2000), 
 Baylis Pain Management Cooled Probe (Baylis Medical Co., Ontario, 
Canada; approved 2005; see also below), 
 Baylis Pain Management Single-Use Probe (Baylis Medical Co.,  
Ontario, Canada; approved 2007), 
 Pajunk RFTL Radiofrequency Needle (Pajunk GmbH  
Medizintechnologie, Geisingen, Germany; approved 2006), 
 Smith & Nephew RF Denervation Probes & RF Cannulae  
(Smith & Nephew Inc., Andover, MA, USA; approved 2004), 
 Stryker RF Electrodes and Cannulae (Stryker Instruments Kalamazoo, 
MI, USA; approved 2004), 
 Radionics disposable RF Cannulae (Technomed Europe,  
The Netherlands; approved 2004) [8]. 
laut Einreichern 
erforderlich: 
- spezialisiertes 
Zentrum 
- erfahrenes OP-Team 
- intraoperatives 
Röntgen 
FDA reguliert  
RFD Produkte  
(nicht spezifisch für  
die Indikation) 
aktuell 7 Systeme von 
der FDA zugelassen 
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The cooled RFD system Sinergy by Baylis Medical Co. Inc, used in the RFD 
studies for sacroiliac joint pain, was acquired by the Kimberly-Clark Corp. 
in 2009. SInergy comprises a pump, generator, and probe. The pump circu-
lates sterile water through the probes. The various Baylis Pain Management 
probes are sterile, single-use devices that deliver RF energy while being cooled. 
The probes are used in conjunction with an RF generator to create RF le-
sions in nerves. All components have received FDA clearance as substantial-
ly equivalent to an approved predicate device.  
The SInergy Pain Management System has also received CE Marking [12]. 
We were not able to identify a comprehensive list of other currently CE mark-
ed RFD systems and we refrained from a manual search for the CE marking 
of various RFD components. 
A0021 – What is the reimbursement status  
of radiofrequency denervation? 
Currently, radiofrequency denervation of the facet and sacroiliac joints can be 
reimbursed via the Austrian DRG-system (Leistungsorientierte Krankenan-
staltenfinanzierung/LKF) using the code AJ140 “percutaneous destruction of 
peripheral nerves”. 
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4 Health Problem and Current Use 
Overview of the disease or health condition 
A0001 – For which health conditions and for what purposes  
is radiofrequency ablation/denervation used? 
Radiofrequency ablation is one of several types of ablation therapy. There-
fore, it can be used to treat a wide range of conditions. For example, RFA is 
sometimes used in oncology [13] to treat (bone, kidney, liver, lung or pros-
tate) cancers or precancerous lesions in the esophagus (Barrett’s esophagus), 
in cardiology [14] to treat arrhythmias (e.g., supraventricular tachyarrhyth-
mias), or in dermatology [15] to treat skin lesions. Finally, RFA is used in 
pain therapy, e.g., for the treatment of neck or low back pain (LBP). 
A0002 – What is the disease or health condition in the scope  
of this assessment?  
In the scope of this assessment, chronic low back pain deriving from the fac-
et or sacroiliac joints is the condition of interest. Low back pain is defined as 
pain and discomfort, localised between the costal margin and above the infe-
rior gluteal folds, with or without referred leg pain, that persists for at least 
12 weeks (European Guidelines from 2004 [16]). The cause for sacroiliac pain 
is a sacroiliac joint dysfunction (due to hypermobility/instability or hypomo-
bility/fixation).  
A0003 – What are the known risk factors for chronic low back pain? 
There are many possible causes for low back pain, e.g., infections, tumours, 
osteoporosis, fractures, or spinal disc herniation. The majority of patients (ap-
proximately 85%) seen in the primary care, however, have non-specific low 
back pain, which is not attributable to a recognisable, known specific pathol-
ogy or anatomical structure (e.g., infection, tumour, osteoporosis, fracture) 
[1, 17]. Suspected sources of back pain include lumbar facet (zygapophyseal) 
joints, sacroiliac joints, and degenerated intervertebral discs [1]. 
Risk factors associated with back pain include smoking, obesity, age, female 
gender, physically strenuous work, sedentary work, psychologically strenuous 
work, low educational attainment, job dissatisfaction, and psychologic factors 
such as somatization disorder, anxiety, and depression [17]. 
A0004 – What is the natural course of chronic low back pain? 
Chronic low back pain is seen as recurring or persistent condition showing a 
fluctuating course over time. It is likely that patients who report LBP will 
continue to report LBP in the future [18]. After an initial episode of low back 
pain, 44-78% of the patients suffer relapses of pain [16]. 
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Effects of the disease or health condition  
on the individual and society 
A0005 – What is the burden of disease for patients with  
chronic low back pain? 
Chronic low back pain is one of the most commonly reported pain conditions. 
It is often characterized by a long duration of illness and multiple recurrent 
episodes of pain. Patients with low back pain often report comorbidities such 
as osteoarthritis, cardiovascular and cerebrovascular diseases, as well as men-
tal disorders, such as depression, anxiety disorders, and post-traumatic stress 
disorder. International data also show a positive correlation between low back 
pain and symptoms, such as migraine and headache, exhaustion, and respir-
atory symptoms [19]. 
A0006 – What are the consequences of chronic low back pain  
for the society? 
Low back pain is one of the most expensive diseases in industrialised coun-
tries. It is one of the most frequent causes for inability to work and early re-
tirement. In Germany, low back pain is estimated to cause direct costs of € 8.4 
billion per year. According to international estimates, 85% of these costs are 
due to productivity losses because of inability to work and the remaining 15% 
are spent for medical treatment [19]. In the United States, costs of low back 
pain have been estimated to be more than 100 billion USD per year, primar-
ily due to lost productivity [10]. 
 
Current clinical management of the disease or health condition 
A0024 – How is chronic low back pain currently diagnosed according  
to published guidelines and in practice? 
Chronic low back pain is diagnosed by a detailed medical history (anamnesis). 
The medical history should include asking for onset of symptoms, duration, 
localisation and causes of pain, correlation of pain with specific positions and 
movements, earlier pain episodes, problems in activities of daily living, as well 
as psychosocial risk factors. An important part of the medical history is ask-
ing for red flag symptoms, which can indicate specific causes (e.g., fracture, 
tumour, infection, radiculopathy/neuropathy) with potentially urgent need for 
action [19, 20]. 
An additional physical examination (e.g., inspection, palpation, test of the mo-
bility of the lumbar spine, examination of the sacroiliac joint [19, 20]) aims 
at distinguishing between non-specific vs. specific (physical or mental) causes 
(as the above mentioned red flag symptoms do). Medical imaging also aims 
at identifying specific causes for low back pain. However, study results ques-
tion its use as single diagnostic modality, because degenerative changes (here: 
ostoartritis of facet joints detected by CT) are common in the general popu-
lation and increasing with age [21]. A large population based study failed to 
find an association of this CT-verified presence of degenerative osteoarthri-
tis and low back pain [21]. 
During the care process, the assessment of psychosocial and somatic risk fac-
tors for pain chronification (‘yellow flags’; e.g., depressiveness, pain-related 
cognition, passive pain behaviour, workplace-related factors, iatrogenic fac-
tors) is recommended [19]. 
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A0025 – How is chronic low back pain currently managed according  
to published guidelines and in practice? 
Conservative treatment options for chronic low back pain may include 
pharmaceuticals (drug therapy [19]),  
 non-steroidal antirheumatics/antiphlogistics (tNSAR), 
 and, if applicable, opioid analgesics, muscle relaxants,  
or antidepressants,  
or non-drug therapies [19],  
 physical activity and movement therapy,  
 therapeutic exercise,  
 patient education (information/training),  
 ergonomics,  
 multimodal, multi-, and interdisciplinary treatment/rehabilitation,  
 self-management programmes,  
 occupational therapy,  
 behavioural therapy, or  
 progressive muscle relaxation.  
According to this guideline, invasive therapeutic procedures are not recom-
mended for the treatment of patients with nonspecific low back pain [19], 
due to the lack of reliable data (despite of numerous studies) for percutane-
ous procedures and the lack of studies on the use of surgical procedures. 
The Austrian Guideline for the management of acute and chronic non-specific 
low back pain, published in 2011 [20], recommends multidisciplinary treat-
ment programmes for chronic low back pain. Single interventions, such as phar-
macological treatment only, are not considered to be sufficient to alleviating 
pain in the long term, as well as to prevent disability and work absences [20].  
 
Target population 
A0007 – What is the target population in this assessment? 
The target population in this assessment are adult patients with chronic low 
back pain (longer than three months), who had a positive response to a dia-
gnostic block in the sacroiliac or facet joints. Patients with acute trauma, frac-
ture, malignancy, and inflammatory disease were excluded [1].  
A0023 – How many people belong to the target population?  
According to a health survey conducted by Statistik Austria in 2014, 23% of 
Austrian men and 26% of Austrian women were affected by chronic low back 
pain or other chronic back problems in the last 12 months. The prevalence 
increases with age and more women are affected than men [22]. The lifetime 
prevalence of low back pain (in total) is estimated to be up to 84% [16]. 
Prevalence-estimates of facet or sacroiliac joint pain are provided by the RFD 
studies’ authors as follows: thus, facet-joint pain accounts for 15% to 50% [6, 
23, 24] and sacroiliac joint pain for 15-20% [4, 25] of low back pain. Against 
the backdrop of the high prevalence of degenerative changes detected in facet 
joints (63% in a sample of 188 men and women, at mean ~52 years old [21]) 
or sacroiliac joints (65% in a sample of 373 men and women, at mean ~58 
years old [26]) of the general population, the provided (high) proportion of 
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‘facet or sacroiliac joint pain’ as causes of low back pain can be questioned. 
Due to non-specific imaging and clinical testing reliable epidemiological data 
seems to be missing. 
A0011 – How much is radiofrequency denervation of the facet and 
sacroiliac joints utilised? 
According to the information provided by one Austrian hospital, the annual 
frequency in this hospital is estimated to be 40 procedures of sacroiliac joint 
radiofrequency denervation. In 2014, 20 treatments were recorded in the sub-
mitting hospital. No estimations were provided regarding the annual frequen-
cy in Austria in total. The number of procedures of facet joint radiofrequency 
denervation in Austrian hospitals is unknown. 
 
Frequenz der Iliosakral-
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5 Clinical effectiveness 
5.1 Outcomes 
The following outcomes were defined as crucial to derive a recommendation: 
 pain 
 functional status 
 global improvement 
 health-related quality of life 
Changes in pain intensity were measured in all included studies using the 
Visual Analogue Scale (VAS) or the Numeric Rating Scale (NRS). The VAS 
is a continuous scale comprised of a horizontal or vertical line, usually 10 cm 
in length. Numbers or verbal descriptors at intermediate points are not rec-
ommended. The NRS (used in [2] and [4, 25]) is a segmented numeric ver-
sion of the VAS. The most commonly used is the 11-item NRS, an 11-point 
numeric scale with 0 representing “no pain” and 10 representing “worst pain 
imaginable” [27]. One study used the Visual Numeric Pain Scale (VNS) for 
pain measurement [23]. 
The functional status was measured using the Oswestry disability index score 
(ODI) in 7 of the included studies. The ODI was published in 1980 and has 
been widely used as a condition-specific outcome measure for patients with 
spinal disorders. It is comprised of 10 items (including pain intensity, per-
sonal care, walking, sleeping, social life, ...) with associated statements for the 
patient to select, which reflect the patient’s ability to manage their everyday 
life. A maximum score of 50 is possible. The score can also be expressed as a 
percentage score (0-20% means minimal disability, 81-100% means that the 
patient is bed-bound) [28]. 
As ‘global improvement’ is a non-specific outcome, study authors used differ-
ent tools to determine potential effects. For assessing the ‘global perceived 
effect’ (GPE, used in two studies [4, 25]), three questions are asked (1. My pain 
has improved/worsened/stayed the same since my last visit; 2. The treatment 
I received improved/did not improve my ability to perform daily activities; 
3. I am satisfied/not satisfied with the treatment I received and would recom-
mend it to others.). Three studies used 4-7 point scales to determine a change 
in the ‘global effect on back pain’[29], the ‘subjective global assessment’ [30]/ 
the ‘global perceived effect’[6].  
Health related quality of life (generic or disease-specific) can be assessed by 
various standardised instruments. Studies included in this review used EQ-5D 
[23], SF-36 [29], and AQoL [4]. 
The outcomes  
 patient satisfaction and  
 ability to work  
were defined as important, but not crucial to derive a recommendation. 
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5.2 Included studies 
Facet joint pain: study and patient characteristics 
Overall, we included 10 studies that evaluated radiofrequency denervation for 
facet joint pain [2, 5, 6, 23, 24, 29-33]. All studies were randomised controlled 
trials. 6 [5, 6, 29-32] compared radiofrequency denervation with a placebo/ 
sham treatment, the remaining 4 studies used steroid injections as the com-
parator [2, 23, 24, 33].  
3 trials were conducted in Turkey [5, 23, 33], 2 in the Netherlands [6, 29], and 
the remaining 5 studies in Canada, Germany, Iran, Sweden, and the UK. The 
two Dutch studies were nationally funded [6, 29], the Swedish, German and 
Canadian study stated no (industry) funding [24, 30]/academic research [32], 
the remaining 5 studies did not provide funding information. The placebo 
controlled trials were published between 1994 and 2008, the remaining 4 stud-
ies between 2012 and 2014. Sample sizes of the placebo-controlled trials ranged 
from 31 to 81, those with the injection control groups included more patients 
by trend (80-120 each, except for one trial with only 56 patients). The total 
number of patients was 323 patients in the 6 placebo-controlled and 356 in 
the 4 steroid injection controlled trials. 
Inclusion criteria differed considerably between studies. In the placebo-con-
trolled trials, patients hat to suffer from back pain for more than 3 months 
[31, 32] up to at least 2 years [30] (>6 months [5, 29], >12 months [6]). In 
the trials with the steroid injection control, patients had to suffer from back 
pain for more than 6 months [2, 33] to >2 years in [24] (not dependant on the 
total duration of complaints, but no response to conservative treatment for up 
to 6 weeks in [23]). 
The mean age of included patients ranged from 41 to 61 years in the placebo 
controlled trials, 50 to 64 years in the steroid injection controlled trials. Pa-
tients in the latter studies were slightly older: none of these studies show mean 
ages below 50 years in comparison to 3 of the 6 placebo-controlled trials. The 
percentage of female participants was more than 55% in all but one (steroid 
comparison) trial (35-39%) [24] with a maximum of up to 75% in [29]. Pa-
tient follow-up ranged from 3 [32] to most commonly 12 months (in half of 
the placebo-controlled [5, 6, 29] as well as steroid controlled [23, 33] trials). 
Loss to follow-up ranged from 0% [5, 23, 29, 30] to 10% in [24], 2 trials did 
not report drop-outs [31, 33]. 
Facet joint pain: quality assessment 
4 of 6 placebo-controlled and 1 of 4 steroid-injection controlled trials have 
been judged to have a low risk of bias on a single study level. The remaining 
5 studies [2, 23, 30, 31, 33] involve a high bias risk, e.g., due to unclear blind-
ing (where possible), unclear or high number of drop-outs, or differing base-
line characteristics. 
Characteristics of included studies are displayed in Table A-1 and Table A-2. 
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Sacroiliac joint pain: study and patient characteristics 
For evaluating radiofrequency denervation for sacroiliac joint pain, 2 random-
ised controlled trials fulfilled the inclusion criteria [4, 25]. Both RCTs com-
pared radiofrequency denervation with placebo/sham treatment. They were 
published 2008-2012, conducted in the US and funded by Baylis Medical. 
The total number of patients was 79. Both RCTs included patients who had 
low back pain lasting for 6 months or longer and who had not achieved ade-
quate improvement after conservative therapies.  
The mean age of patients was 52-64 years. 57-82% of the patients were female. 
Length of follow-up was 6 [25] and 9 months [4]. However, patients of the con-
trol group were given the opportunity to cross-over after 1 [25] or 3 [4] months.  
No lossestofollow-up were observed up to 3 months. 
Sacroiliac joint pain: quality assessment 
One RCT was judged to have a low bias risk [4], whereas the other RCT [25] 
might imply a high risk due to differing baseline characteristics.  
Characteristics of included studies are displayed in Table A-4. 
 
 
5.3 Results 
Mortality 
D0001 – What is the expected beneficial effect of radiofrequency 
denervation on mortality? and  
D0003 – What is the effect of radiofrequency denervation  
on the mortality due to causes other than low back pain? 
Mortality is not a relevant outcome for assessing the clinical effectiveness of 
radiofrequency denervation, since neither the disease nor the intervention is 
life-threatening. Therefore, none of the included studies reported this outcome. 
 
Morbidity (Pain) 
D0005 – How does radiofrequency denervation affect symptoms  
and findings (severity, frequency) of chronic low back pain? 
Facet joint pain 
All 6 placebo-controlled trials report pain outcomes as changes in VAS score. 
Up to one month, one study reports statistically significant group differences 
in favour of the intervention at the post procedure observation point (conven-
tional or pulsed RFD compared to placebo) [5]. One month after the inter-
vention, statistically significant group differences are only observed in a sub-
group comparison of one trial [31], whereas the third study doesn’t observe a 
statistically significant group difference [32] (The overall estimate up to/in-
cluding one month post intervention is statistically significant in favour of 
the intervention: MD -1.47 [-2.28, -0,67]). In the time period up to 6 months, 
only one [6] trial (of the three studies that report VAS group differences in 
this observation period) finds a statistically significant group difference (the 
overall estimate is n.s.: MD -0.71 [-2.25, 0.84]) [6, 29, 32]. At 6 months, 2 [5, 
31] of 3 trials report statistically significant group differences, but the over-
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all estimate remains marginal, non-significant (MD -0.70 [-1.48, 0.08] [5, 30, 
31]). A twelve months result is only provided by one trial, which reports a sta-
tistically significant difference only between the placebo and the conventional 
RFD group (not in comparison with the pulsed RFD group; overall: MD -0.96 
[-0.04, 0.12]) [5].  
In comparison to steroid injections, both studies that report pain outcomes 
at ≤1 month find statistically significant group differences (overall estimate 
MD: -1.81 [-3.05, -0.58]) [23, 33]. Overall estimates for group differences at 6 
and 12 months are also statistically significant (at 6 months [23, 24, 33]: MD 
-2.13 [-3.45, -0.81], only one trial reported a n.s. difference [24]); at 12 months 
[23, 33]: MD -2.65 [-3.43, -1.88]). The remaining trial [2] states significant 
group differences at 12 weeks and 6 months (not at 6 weeks), but doesn’t pro-
vide detailed data. 
Sacroiliac joint pain 
At one month, one study [25] reported a significant reduction in pain, where-
as the second study [4] was not able to detect a significant group difference 
(overall estimate MD -2.21 [-5.34, 0.92]). Meaningful results at 3 months can 
only be provided by one of the two trials [4] (which reports a significant group 
difference; MD -1.30 [-2.06, -0,54]). At this observation point, data of the sec-
ond trial is without value for the comparison due to cross over (only three pa-
tients of the original placebo group declined to cross over to the RFD group) 
[25]. 
D0006 – How does radiofrequency denervation affect progression  
(or recurrence) of chronic low back pain? 
Due to the lack of long-term follow-up data (>12 months), this question can-
not be answered. 
 
Functional status 
D0016 – How does the use of radiofrequency denervation  
affect activities of daily living? 
Facet joint pain 
3 of the 6 placebo-controlled trials report ODI outcomes [5, 6, 32]2. One study 
[5] observes significant group differences between the RFD and control groups 
post procedure, as well as at 6 and 12 months. A statistically significant group 
difference has also been reported in the second trial 8 weeks post interven-
tion. On the contrary, the third study wasn’t able to detect statistically signif-
icant group differences (neither at 4, nor at 12 weeks) [32]. Overall estimates 
at the different observation periods are non-significant within the first 6 months 
(≤1 month: MD -3.45 [-7.68, 0.77]; >1 to <6 months: MD -9.48 [-28.73, 9.76]; 
2 studies each) and significant in favour of the intervention in the following 
6 months (based on one trial). A forth study reported functional status as 
‘mean change in physical activity’ [29] at 3 months (n.s. group difference), 
the remaining 2 studies did not report this outcome [30, 31]. 
                                                             
2 in [18] a n.s. group difference (-3.13 vs. -1.62) was reported, when the functional sta-
tus was measured by the COOP/WONCA Functional Assessment Charts at 8 weeks 
(in contrary to the s. difference if measured by ODI) 
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In comparison to steroid injections, only one trial provides data [24] (for on-
ly one observation point at 6 months) and does not find a statistically signifi-
cant group difference (MD: -5.00 [-15.19, 5.19]). The most recent trial [2] re-
ports statistically significant group differences at 12 weeks and 6 months (n.s. 
at 6 weeks), but doesn’t provide detailed data (results are shown in a figure 
only). The remaining 2 studies did not report this outcome [23, 33]. 
Sacroiliac joint pain 
Both trials provide ODI data [4, 25] and both report statistically significant 
group differences at 1 month (if changes from baseline are compared; the over-
all effect for the group comparisons at 1 month is n.s.: MD -14.06 [-30.42, 
2.30]). Meaningful results at 3 months can only be provided by one of the 
two trials [4] (still significant difference; MD -11.00 [-17.91, -4.09]), whereas 
at this observation point, data of the second trial is without value for the com-
parison due to cross over (only three patients of the original placebo group 
declined to cross over to the RFD group)[25]. 
 
Global improvement 
D0005 – How does radiofrequency denervation affect symptoms  
and findings (severity, frequency) of chronic low back pain? 
In addition to changes in pain or functional status, overall ‘global improve-
ment’ has been assessed in 5 (placebo-controlled) trials with different instru-
ments (no overall estimates provided). 
Facet joint pain 
In an observation period of 2-6 months post intervention, 3 studies reported 
significant global improvements in the RFD group compared to the placebo 
control [6, 29, 30].  
Sacroiliac joint pain 
In an observation period of 1-3 months post intervention, each study reports 
significant global improvements in the RFD group compared to the placebo 
control [4, 25]. 
 
Health-related quality of life 
D0012 – What is the effect of radiofrequency denervation (RFD)  
on generic health-related quality of life? 
Facet joint pain 
One placebo-controlled study [29] on facet joint pain used the SF-36 to meas-
ure quality of life at 3 months post intervention and did not observe statisti-
cally significant group differences (except for the item vitality). 
One study comparing RFD in facet joints with steroid injections didn’t find 
any statistically significant differences in quality of life assessed by the EQ-5D 
(at 1, 6 and 12 months) [23]. 
The remaining 8 studies did not report this outcome. 
Facettengelenke/RFD 
vs. Steroidinjektionen  
(1 RCT) 
 
n.s. 6 Monate post 
Intervention (keine 
anderen Beobachtungs-
zeitpunkte verfügbar) 
Iliosakralgelenke/RFD 
vs. Plazebo (2 RCTs) 
 
insgesamt n.s. 1 Monat 
post Intervention  
(die beiden Einzelstudien 
berichten jedoch  
s. Verbesserungen),  
s. zu Gunsten der 
Intervention nach  
3 Monaten (hier 1 Studie) 
Allgemeine 
Verbesserung: 
Facettengelenke/RFD 
vs. Plazebo (3 RCTs):  
s. Gruppenunterschiede 
nach 2-6 Monaten 
Iliosakralgelenke/RFD 
vs. Plazebo: s. besser 
nach 1 bzw. 3 Monaten 
(je ein RCT) 
Lebensqualität 
(generisch): 
Facettengelenke/RFD 
vs. Plazebo: 1 RCT,  
n.s. nach 3 Monaten; 
vs. Steroidinjektion  
(1 RCT): n.s. nach  
1-12 Monaten 
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Sacroiliac joint pain 
One of the two studies on RFD in SI joints used the AQoL instrument and 
reported no difference at one, but a statistically significant difference at 3 
months [4]. The second study did not report this outcome [25]. 
D0013 – What is the effect of radiofrequency denervation  
on disease-specific quality of life? 
None of the studies reported on disease-specific quality of life. 
 
Ability to work 
D0016- How does the use of radiofrequency denervation  
affect activities of daily living? 
In addition to the measurement of the functional status (see above), this ques-
tion should have been answered by the outcome “ability to work”, but none 
of the RCTs reported this outcome.  
 
Patient satisfaction 
D0017 – Was the use of radiofrequency denervation worthwhile? 
To answer this research question, the outcome “satisfaction with treatment” 
was used.  
Facet joint pain 
The outcome was reported in 1 of 6 placebo controlled RCTs on RFD in facet 
joints and 3 of 4 RCTs comparing RFD with steroid injections in facet joints.  
Compared to the placebo intervention, one study reported significantly higher 
patient satisfaction (≥1 month) in the intervention group without providing 
detailed data [5]. 
Compared to steroid injections one study [23] reported no difference in pa-
tient satisfaction at 1 and 6 months (whereas the 12 month result favoured 
RFD). The remaining two studies found significant group differences in fa-
vour of RFD at all observation points (after 12 weeks and 6 months [2], at 1, 
6 and 12 months [33]). 
Sacroiliac joint pain 
The two RCTs assessing RFD in the sacroiliac joint did not report on patient’s 
satisfaction with treatment [4, 25]. 
 
Iliosakralgelenke/RFD 
vs. Plazebo:  
1 RCT, n.s. nach 1,  
s. nach 3 Monaten  
 
Lebensqualität 
(indikations-spezifisch): 
Effekt aufgrund 
fehlender Daten 
unbekannt 
Arbeitsfähigkeit: 
Effekt aufgrund 
fehlender Daten 
unbekannt 
PatientInnen-
zufriedenheit 
Facettengelenke/RFD 
vs. Plazebo (1 RCT):  
„s. besser“ (ohne Daten) 
vs. Steroidinjektion (3 
RCTs): widersprüchliche 
Studienergebnisse, 
tendenziell zu Gunsten 
der Intervention 
Iliosakralgelenke/RFD 
vs. Plazebo: Effekt 
aufgrund fehlender 
Daten unbekannt 
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6 Safety 
6.1 Outcomes 
The following outcome was defined as crucial to derive a recommendation: 
 Complications 
The outcome ‘complications’ is non-specific and includes direct intervention-
related side-effects (e.g., during or immediately after the intervention), as well 
as any other negative consequences observed in the follow-up period. 
 
 
6.2 Included Studies 
Facet joint pain: study and patient characteristics 
In addition to the 10 studies [2, 5, 6, 23, 24, 29-33] that we had already in-
cluded for the clinical effectiveness assessment, we included 3 further RCTs 
[34-36] for the safety analysis. All of these studies compared different RFD 
methods (continuous vs. pulsed RFD [34], a distal vs. a tunnel vision approach 
for RFD [35] and an intra-articular vs. extra-articular RFD [36]). 
The trials were conducted in the US [34], Korea [35] and the Netherlands, [36] 
and published between 1999 [36] and 2013 [35]. Sample sizes ranged from 34 
[36] to 82 [35]. The total number of patients was 166. Inclusion criteria varied 
between studies. Patients had to suffer from back pain for more than 1 [34], 
3 [35], or 6 months [36]. 
The mean age of included patients ranged from 57 to 69 years. The percent-
age of female participants differed considerably between and within studies 
(24-29% [36], 46-62% [34] and 62-72% [35]). Patient follow-up ranged from 
3 [34, 36] to 6 [35] months, loss to follow-up was from 12-15% [35] to 48% in 
[34] ([36]did not report drop-outs). 
Facet joint pain: quality assessment  
All 3 RCTs were judged to have a high risk of bias due to the unclear/high 
number of drop-outs, unclear blinding, and allocation concealment processes. 
For the study and patient characteristics of the further 10 RCTs, see the de-
scription of included studies in the section on clinical effectiveness. 
Study characteristics and results of included studies are displayed in Table 
A-1, Table A-2, and Table A-3, and in the evidence profile in Table 7-3. 
Sacroiliac joint pain: study and patient characteristics 
The 12 month follow up [3] of Patel 2012 [4] (which could have been includ-
ed for safety issues despite cross-over) didn’t provide any safety data. There-
fore, we included the same 2 RCTs [4, 25] (that we had already included for 
the clinical effectiveness assessment) for evaluating the safety of RFD for sa-
croiliac joint pain (see 5.2).  
Study characteristics and results of included studies are displayed in Table 
A-4 and in the evidence profile in Table 7-5. 
für den Bereich 
Sicherheit wurden 
‚Komplikationen’  
als entscheidender 
Ergebnisparameter 
definiert 
Schmerzen im Bereich 
der Facettengelenke: 
13 RCTs:  
10 (siehe Wirksamkeit)  
+ 3 RCTs,  
die unterschiedliche 
RFD Methoden 
verglichen (1999-2013, 
166 PatientInnen) 
Alter: 57-69 Jahre, 
Frauenanteil 24-72 %;  
Drop-out in einer Studie 
48 % 
alle 3 RCTs mit  
hohem Biasrisiko 
Schmerzen im Bereich 
der Iliosakralgelenke: 
2 RCTs  
(siehe Wirksamkeit)  
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6.3 Results 
Patient safety 
C0008 – How safe is radiofrequency denervation in comparison  
to placebo or steroid injections? 
RFD for facet joint pain (compared to placebo) 
5 of the 6 placebo controlled studies reported no complications at all [5, 6, 
30-32]. The remaining study observed no significant group differences ‘in the 
occurrence of treatment-related pain and subjective sensory or motor chang-
es’ [29]. 
RFD for facet joint pain (compared to steroid injections) 
2 studies observed no complications/adverse events [24, 33]. Study authors 
of one trial stated that no infections or new motor or sensory deficits occurred, 
rare complaints of small superficial burns after RFD were reported, and an 
increase in severity of low back pain had been observed in 2 RFD group pa-
tients (of 50; 4%) in the early follow-up period [23]. The remaining trial did 
not report safety outcomes [2]. 
RFD for sacroiliac joint pain (compared to placebo) 
None of the two studies reported any serious complications [4, 25]. 
Authors of one study state that ‘a majority of patients reported temporary 
worsening pain’ (procedure-related pain and/or temporary neuritis up to 5-
10 days after the procedure). It can be assumed, but it is not clearly stated, 
that/if this observation was made for both groups. In addition, they report 
‘one patient reported transient nonpainful buttock paresthesia that resolved 
without therapy’ (=1/25 pts. due to crossover (4%))[25]. 
The second study only reports a ‘small proportion of subjects with soreness 
or numbness at the introducer sites in the 2 weeks following treatment’ and 
that one patient developed shingles at the introducer site (seen as unrelated 
to the treatment) [4]. Again, a between group distinction cannot be made be-
cause this information has not been provided. 
C0002 – Are there harms related to dosage or frequency  
of applying radiofrequency denervation? 
Facet joint pain 
The trial comparing continuous RFD (performed at 80° C for 75 seconds) with 
pulsed RFD (at 42° C with pulse duration of 20 milliseconds and pulse rate 
of 2 Hz for 120 seconds) did not encounter any adverse event (in any group) 
during the intervention or up to 3 months post-procedure (this observation 
relies on the 26 of 50 patients (only 52%) who completed the 3 months fol-
low-up) [34]. 
The trial comparing intra- with extra-articular RFD stated that with ‘no com-
plications’ were observed (34 patients, 3 months observation period, loss to 
follow-up not reported)[36]. 
Komplikationen: 
 
Facettengelenke/RFD 
vs. Plazebo (6 RCTs): 
„keine Komplikationen/ 
Gruppenunterschiede“ 
vs. Steroidinjektionen  
(3 RCTs): „keine 
Komplikationen“ bzw. 
selten oberflächliches 
Brennen/stärkere 
postinterventionelle 
Schmerzen bei RFD 
Iliosakralgelenke/RFD 
vs. Plazebo (6 RCTs): 
„keine schwerwiegenden 
Komplikationen“ 
stärkere  
postinterventionelle 
Schmerzen/ggfs. 
Taubheitsgefühl  
Unterschiede bezüglich 
Dosis/Häufigkeit der 
Anwendung: 
 
Vergleiche von pulsed 
vs. continous RFD  
sowie von intra- und 
extraartikulärer RFD 
berichten von „keinen 
Komplikationen“ 
Safety 
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The direct comparison of two techniques (distal vs. tunnel vision approach) 
found one complication (2%) in the distal approach group (localised pain) 
and 5 complications (10%) in the tunnel vision approach group (2 patients 
with localised pain and 3 with new neuropathy-like pain lasting >3 months) 
during the 6-month follow-up [35]. However, this group difference was not 
statistically significant. 
Sacroiliac joint pain 
No evidence was identified to answer the research question. 
C0004 – How does the frequency or severity of harms change  
over time or in different settings? 
No evidence was identified to answer the research question. 
C0005 – What are the susceptible patient groups that are more likely  
to be harmed through the use of radiofrequency denervation? 
No evidence was identified to answer the research question. 
C0007 – Are radiofrequency denervation, placebo interventions,  
or steroid injections associated with user-dependent harms? 
No evidence was identified to answer the research question. 
 
 
 
 
Vergleiche von distal vs. 
tunnel vision approach 
berichten von mehr 
(n.s.) Komplikationen 
mit letzterer Technik 
Veränderung  
durch verschiedene 
Settings/im Zeitverlauf 
unbekannt 
vulnerable Gruppen 
unbekannt 
AnwenderInnen- 
bedingte 
Komplikationen 
unbekannt 
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7 Quality of evidence 
The strength of evidence was rated according to GRADE (Grading of Recom-
mendations Assessment, Development and Evaluation) scheme [37] for each 
endpoint individually. Each study was rated by two independent researchers. 
In case of disagreement a third researcher was involved to solve the differ-
ence. A more detailed list of criteria applied can be found in the recommen-
dations of the GRADE Working Group [37].  
GRADE uses four categories to rank the strength of evidence: 
 High = We are very confident that the true effect lies close  
to that of the estimate of the effect;  
 Moderate = We are moderately confident in the effect estimate:  
the true effect is likely to be close to the estimate of the effect, but 
there is a possibility that it is substantially different;  
 Low = Our confidence in the effect estimate is limited: the true  
effect may be substantially different from the estimate of the effect;  
 Very low = Evidence either is unavailable or does not permit  
a conclusion. 
The ranking according to the GRADE scheme for the research question can 
be found in Table 7-1 to Table 7-5.  
RFD for facet joint pain 
Overall, the strength of evidence for the effectiveness and safety of radiofre-
quency denervation for facet joint pain in comparison to placebo (sham in-
tervention) is low: 
There is low evidence that RFD compared to placebo 
 might reduce pain in the short term (≤1 month),  
but not in the intermediate term (>1 to 12 months), 
 might not increase functional status <6 months,  
but between 6 to 12 months, 
 might not improve quality of life at 3 months, 
 might lead to a global improvement in the intermediate term  
(>1 up to 6 months). 
There is very low evidence that RFD compared to placebo 
 might not increase complications. 
For the outcome quality of life and global improvement (≤1 and >6 months), 
no evidence is available.  
1. Overall, the strength of evidence for the effectiveness and safety of radio-
frequency denervation for facet joint pain in comparison to steroid injec-
tions is low to very low:  
There is low evidence that RFD compared to steroid injections 
 might reduce pain up to 12 months post intervention.  
 
Qualität der Evidenz 
nach GRADE 
Facettengelenks-RFD  
vs. Plazebo 
insgesamt geringe 
Evidenz, z. B.: 
kurzfistige 
Schmerzreduktion  
(<1 Monat),  
nicht längerfristig 
sehr geringe Evidenz, 
dass Komplikationen 
nicht zunehmen 
Facettengelenks-RFD  
vs. Steroidinjektionen 
insgesamt (sehr) geringe 
Evidenz, z. B.: Schmerz-
reduktion bis zu 1 Jahr, 
keine Funktionalitäts-
verbesserung 
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There is very low evidence that RFD compared to steroid injections 
 might not improve the functional status in the intermediate term  
(≥6 to <12 months), 
 might not improve quality of life up to 12 months, 
 does not lead to complications/major adverse events, infections or 
motor or sensory deficits, but might cause superficial burns after the 
intervention and an initial increase in back pain. 
For the outcome global improvement, no evidence is available (as well as 
for: pain >1 to <6 months, functional status <6 and ≥12 months and 
health related quality of life >1 to <6 months). 
2. Based on studies that compared different RFD techniques, there is very 
low evidence of no complications/major adverse events, but mild local-
ised pain (<1 month) or neuropathy like pain (>3 months) had been ob-
served in 2-12% of patients. 
RFD for sacroiliac joint pain 
1. Overall, the strength of evidence for effectiveness and safety of radiofre-
quency denervation for sacroiliac joint pain in comparison to placebo 
(sham intervention) is low to very low: 
There is low to very low evidence that RFD compared to placebo 
 might not reduce pain or improve functional status in the short term 
(≤1 month), but thereafter up to 3 months, 
 might lead to a global improvement up to 3 months, 
 might not increase quality of life up to 1, but up to 3 months.  
There is very low evidence that RFD compared to placebo 
 might not increase serious complications. 
No evidence is available for all critical outcomes (pain, functional status, 
global improvement, health related quality of life) in an observation pe-
riod of >3 months. 
 
sehr geringe Evidenz, 
dass keine 
(schwerwiegenden) 
Komplikationen 
auftreten 
keine Evidenz zu 
allgemeiner 
Verbesserung 
Iliosakralgelenks-RFD 
vs. Plazebo 
insgesamt (sehr) 
geringe Evidenz, z. B.: 
Schmerzreduktion  
und Funktionalitäts-
verbesserung  
>1 bis < 3 Monate 
sehr geringe Evidenz, 
dass keine (schwerwie-
genden) Komplikationen 
auftreten  
 
keine Evidenz >3 Monate 
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Table 7-1: Evidence profile for RFD vs. placebo: efficacy in patients with facet joint pain  
No of studies/patients 
Study 
Design Estimate of effect 
Study 
limitations Inconsistency Indirectness 
Other modifying 
factors 
Strength of 
evidence 
Efficacy (RFD vs. placebo) 
pain 
pain intensity (VAS), ≤1 month 
3/160 (94 vs. 66) [5, 31, 32]  RCT MD -1.47 [-2.28, -0,67] 0 -1 0 -11 low 
pain intensity (VAS), >1 to <6 months 
3/182 (91 vs. 91) [6, 29, 32] RCT MD -0.71 [-2.25, 0.84] 0 -1 0 -11 low 
pain intensity (VAS), ≥6 to <12 months 
3/130 (78 vs. 52) [5, 30, 31] RCT MD -0.70 [-1.48, 0.08] 0 -1 0 -11 low 
pain intensity (VAS), ≥12 months 
1/60 (40 vs. 20) [5] RCT MD -0,96 [-0,04, 0.12]* 0 -1 (NA) 0 -11 low 
functional status 
functional status (ODI), ≤1 month  
2/130 (76 vs. 54) [5, 32] RCT MD -3,45 [-7,68; 0,77]* 0 -1 0 -11 low 
functional status (ODI), >1 to <6 months3 
2/101 (51 vs. 50) [6, 32] RCT MD -9.48 [-28.73; 9.76]4* 0 -1 0 -11 low 
functional status (ODI), ≥6 to < 12 months  
1/60 (40 vs. 20) [5] RCT -3,7 [-6,94;-0,47]* 0 -1 (NA) 0 -11 low 
functional status (ODI), ≥12 months 
1/60 (40 vs. 20) [5] RCT -5,33 [-8.56; -2.11]* 0 -1 (NA) 0 -11 low 
global improvement 
Global improvement, ≤1 month  
NR 
global improvement, >1 to <6 months  
2/112 (55 vs. 57) [6, 29] RCT at 8 weeks [6]: 1,33 vs. 0,37 (s.) 
at 3 months [29]: 61.5% vs. 39.0% (s.) 
0 -1 0 -11 low 
                                                             
3 In addition, Van Wijk [27] reports mean changes in physical activity (as functional outcome) and finds n.s. group differences at 3 months 
4 VanKleef [20] didn’t provide standard deviations (SD) for the ODI scores at 8 weeks. The shown calculation is based on the given SDs for the baseline data.  
The estimated effect remains comparable even if the SDs are halved (-9.95 [-29.22, 9.32]) or doubled (-7.64 [-26.38, 11.09]). 
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No of studies/patients 
Study 
Design Estimate of effect 
Study 
limitations Inconsistency Indirectness 
Other modifying 
factors 
Strength of 
evidence 
global improvement, ≥6 to <12 months  
1/40 (20 vs. 20) [30] RCT at 6 months: -1.1 vs. -0,3 (s.) 0 -1 (NA) 0 -11 low 
global improvement, ≥12 months 
NR 
health related quality of life 
health related quality of life, ≤1 month  
NR 
health related quality of life, >1 to <6 months  
1/81 (40 vs. 41) [29] RCT (SF-36 general health) at 3 months:  
1.8 (13.6) vs. -1.3 (17.5) (n.s.) 
0 -1 (NA) 0 -11 low 
global improvement, ≥6 to <12 months  
NR 
health related quality of life, ≥12 months 
NR 
 
ability to work 
NR 
satisfaction with treatment 
1/60 (40 vs. 20) [5] RCT “higher in IGs than CGs” (s.) 0 -1 (NA) 0 -11 low 
complications (RFD vs. placebo) 
6/323 (175 vs. 148) [5, 6, 29-32] RCT 5 of 6 studies reported “no complications”, 1 study [29] 
reported “no significant differences between groups” 
0 -1 0 -11 low 
* own calculation;  
1 downgraded due to imprecise data; bold font indicates statistically significant group difference(s.) 
Nomenclature for GRADE table:  
Limitations: 0: no limitations or no serious limitations; -1: serious limitations  
Inconsistency: NA: Not applicable (only one trial); 0: no important inconsistency; -1: important inconsistency  
Indirectness: 0: direct, no uncertainty, -1: some uncertainty, -2 major uncertainty  
Other modifying factors: publication bias likely (-1), imprecise data (-1)1, strong or very strong association (+1 or +2), dose-response gradient (+1), Plausible confounding (+1)  
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Table 7-2: Evidence profile for RFD vs. steroid injections: efficacy in patients with facet joint pain  
No of studies/patients 
Study 
Design Estimate of effect 
Study 
limitations Inconsistency Indirectness 
Other modifying 
factors 
Strength of 
evidence 
Efficacy (RFD vs. steroid injections) 
Pain 
pain intensity (VAS), ≤1 month  
2/180 (90 vs. 90) [23, 33] RCT MD -1.81 [-3.05, -0,58]*+ -1 0 0 -11 low 
pain intensity (VAS), >1 to <6 months 
NR** 
pain intensity (VAS), ≥6 to <12 months 
3/232 (116 vs. 116) [23, 24, 33] RCT MD -2.13 [-3.45, -0.81]** -1 0 0 -11 low 
pain intensity (VAS), ≥12 months 
2/180 (90 vs. 90) [23, 33] RCT MD -2.65 [-3.43, -1.88]+ -1 0 0 -11 low 
Functional status 
Functional status, ≤1 month  
NR 
Functional status, >1 to <6 months 
NR** 
functional status (ODI), ≥6 to <12 months 
1/52 (26 vs. 26) [24] RCT MD -5.00 [-15.19, 5.19]** -1 -1 (NA) 0 -11 very low 
functional status, ≥12 months 
NR 
Global improvenement 
NR 
Health related quality of life 
Health related quality of life, ≤1 month  
1/100 (50 vs. 50) [23] RCT -8.2 vs -8.7 (n.s.) -1 (-1) NA 0 -11 very low 
Health related quality of life, >1 to <6 months 
NR 
Health related quality of life, ≥6 to <12 months 
1/100 (50 vs. 50) [23] RCT -7.3 vs -7.5 (n.s.) -1 (-1) NA 0 -11 very low 
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No of studies/patients 
Study 
Design Estimate of effect 
Study 
limitations Inconsistency Indirectness 
Other modifying 
factors 
Strength of 
evidence 
Health related quality of life, ≥12 months 
1/100 (50 vs. 50) [23] RCT -7.1 vs -6.7 (n.s.) -1 (-1) NA 0 -11 very low 
ability to work 
NR 
satisfaction with treatment*** 
satisfaction with treatment, ≤1 month  
1/100 (50 vs. 50) [23]  
1/120 (80 vs. 40) [33] 
RCT at 1 month: 
1.3 vs. 1.3 (n.s.) [23] 
3.2 vs. 2.6 (s.) [33] 
-1 -1 0 -11 very low 
satisfaction with treatment, >1 to <6 months 
1/80 (40 vs. 40) [2] RCT at 12 weeks: higher in IG than KG (s.) -1 (-1) NA 0 0 very low 
satisfaction with treatment, ≥6 to <12 months 
1/80 (40 vs. 40) [2] 
1/100 (50 vs. 50) [23] 
1/120 (80 vs. 40) [33] 
RCT at 6 months: 
higher in IG than KG (s.) [2] 
1.4 vs. 1.7 (n.s.) [23] 
3.2-3.6 vs. 2.7 (s.) [33] 
-1 -1 0 -11 very low 
satisfaction with treatment, ≥12 months 
1/100 (50 vs. 50) [23] 
1/120 (80 vs. 40) [33] 
RCT at 12 months: 
1.5 vs. 2.0 (s.) [23] 
3.1-3.2 vs. 2.70 (s.) [33] 
-1 0 0 -11 very low 
Abbreviations: MD mean difference; ODI Oswestry Disability Index; RCT randomized controlled trial; VAS Visual Analogue Scale;  
1 downgraded due to imprecise data; bold font indicates statistically significant group difference(s.) 
* own calculation;  
+ difference also significant between the RFD plus steroid injection and the injection only group (-4,2 vs. -1,7) [33]  
** Hashemi et al [2] do not provide data for the between group differences for pain (VAS) and ODI at 6 weeks, 12 weeks and 6 months (only figure given).  
They state no significant group differences at 6 weeks (VAS p=0.75, ODI p=0,31), but significant group differences favoring the intervention at 12 weeks (VAS p=0.012; ODI p=0.022) and  
6 months (VAS p=0.02; ODI p=0.03)  
*** All three studies that reported patient satisfaction with treatment used a 4 point scale.  
In [2] and [33] a higher number indicates higher patient satisfaction (max. 4) whereas in [23] a lower NASS score (min. 1) reflects higher patient satisfaction. 
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Table 7-3: Evidence profile for RFD vs. placebo, steroid injections or alternative RFD: safety in patients with facet joint pain  
No of studies/patients 
Study 
Design Estimate of effect 
Study 
limitations Inconsistency Indirectness 
Other modifying 
factors 
Strength of 
evidence 
Safety 
complications (RFD vs. placebo) 
6/323 [5, 6, 29-32] RCT 5 of 6 studies reported “no complications”, 1 study [29] 
reported “no significant differences between groups” 
-1 -1 0 -11 very low 
complications (RFD vs. steroid injections) 
3/276 [23, 24, 33]  RCT no complications [33]; no major adverse events [24];  
no infections or motor or sensory deficits [23];  
rare complaints of superficial burns after RFD [23] 
-1 -1 0 -11 very low 
complications (RFD vs. other RFD) 
3/142 [34-36] RCT no complications [36]/no major adverse events [34]; 
mild localised pain <1 month or neuropathy like pain 
>3 months: 1/41 distal vs. 5/41 tunnel vision approach [35] 
-1 -1 0 -11 very low 
1 downgraded due to imprecise data 
Table 7-4: Evidence profile: efficacy of RFD vs. placebo in patients with sacroiliac joint pain  
No of studies/patients 
Study 
Design Estimate of effect 
Study 
limitations Inconsistency Indirectness 
Other modifying 
factors 
Strength of 
evidence 
Efficacy 
Pain 
Pain intensity (NRS), ≤1 month 
2/79 (48 vs. 31) [4, 25] RCT MD -2,21 [-5.34, 0,92]* -1 -1 0 -11 very low 
Pain intensity (NRS), >1 to <6 months 
1/51 (34 vs. 17) [4] RCT MD -1.30 [-2.06, -0.54] 0 -1 (NA) 0 -11 low 
pain intensity (NRS), ≥6 to <12 months 
NR 
pain intensity (NRS), ≥12 months 
NR 
Functionality 
Functional status (ODI), ≤1 month 
2/75 (46 vs. 29) [4, 25] RCT MD -14.06 [-30.42, 2.30] -1 -1 0 -11 very low 
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No of studies/patients 
Study 
Design Estimate of effect 
Study 
limitations Inconsistency Indirectness 
Other modifying 
factors 
Strength of 
evidence 
Functional status (ODI), >1 to ≥6 months 
1/49 (34 vs. 15) [4] RCT MD -11.00 [-17.91, -4.09] 0 -1 (NA) 0 -11 low 
Functional status (ODI), ≥6 to <12 months 
NR 
Functional status (ODI), ≥12 months 
NR 
Global improvement 
Global improvement (positive GPE % (95% CI)), ≤1 month 
1/18 (14 vs. 14) [25] RCT 93 (78-100) vs. 21 (2-45) (s.) -1 -1 (NA) 0 -11 very low 
Global improvement (positive GPE % (95% CI)), >1 to ≥6 months 
1/51 (34 vs. 17) [4] RCT 47 (29-65) vs. 8 (0-36) (s.) 0 -1 (NA) 0 -11 low 
Global improvement (positive GPE % (95% CI)), ≥6 to <12 months 
NR 
Global improvement (positive GPE % (95% CI)), ≥12 months 
NR 
Health related quality of life 
Health related quality of life (AQoL), ≤1 month 
1/51 (34 vs. 17) [4] RCT 0 (0.07 vs. 0.07 (n.s.)) 0 -1 (NA) 0 -11 low 
Health related quality of life (AQoL), >1 to ≥6 months 
1/51 (34 vs. 17) [4] RCT 0.09 vs. 0.02 (s.) 0 -1 (NA) 0 -11 low 
Health related quality of life (AQoL), ≥6 to <12 months 
NR 
Health related quality of life (AQoL), ≥12 months 
NR 
Ability to work 
NR 
Satisfaction with treatment 
NR 
Abbreviations: MD mean difference; ODI Oswestry Disability Index; RCT randomized controlled trial; VAS Visual Analogue Scale; 
1 downgraded due to imprecise data; bold font indicates statistically significant group difference (s.); *own calculation 
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Table 7-5: Evidence profile for RFD vs. placebo: safety in patients with sacroiliac joint pain  
No of studies/patients 
Study 
Design Estimate of effect 
Study 
limitations Inconsistency Indirectness 
Other modifying 
factors 
Strength of 
evidence 
Safety 
complications (RFD vs. placebo) 
2/79 (48 vs. 31) [4, 25] RCT “no serious complications” [4, 25]; 
“majority with temporary worsening pain” [25]; 
“small portion of pts. with soreness or numbness” [4]; 
1 (of 25 IG pts.) transient buttock paresthesia [25] 
-1 -1 0 -11 very low 
1 downgraded due to imprecise data 
Nomenclature for GRADE table:  
Limitations: 0: no limitations or no serious limitations; -1: serious limitations  
Inconsistency: NA: Not applicable (only one trial); 0: no important inconsistency; -1: important inconsistency  
Indirectness: 0: direct, no uncertainty, -1: some uncertainty, -2 major uncertainty  
Other modifying factors: publication bias likely (-1), imprecise data (-1), strong or very strong association (+1 or +2), dose-response gradient (+1), Plausible confounding (+1)  
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8 Discussion 
Interpretation of findings 
Study quality, validity of endpoints, and overall level of evidence 
Overall, the level of evidence for the estimated effects is very low to low. This 
conclusion is primarily based on the following observations: 
Despite the chosen adequate study design (randomised controlled trials), the 
risk of bias of the majority of included single studies can be assumed to be 
high. While the placebo-controlled trials aimed at (and most likely succeeded 
in) blinding the patients and outcome assessors, the studies that compared 
RFD to steroid injection therapy inevitably carry this high bias risk because 
of the impossibility to conceal the group allocation from the patients. The 
relevance of this non-blinding is due to the implications for the validity of 
measured outcomes. All relevant, therefore chosen, and also reported efficacy 
outcome parameters (pain, functional status, overall improvement, health re-
lated quality of life and patient satisfaction) rely on patient self-report, which 
is likely to be susceptible to the knowledge of having or having not received 
the “best available” treatment. This effect might have led to the better results 
(by trend) in the facet-joint RFD vs. steroid injection comparisons than in those 
compared to the sham intervention. Better results for pain reduction observed 
in the comparison with a therapeutic comparator (steroid injections) than with 
a sham intervention (which is not likely to provide more than a placebo ef-
fect) seem otherwise hardly explainable, at least, as far as the population is 
comparable to a certain degree. Only a substantial change in the RFD tech-
nique over time (the steroid injection controlled facet joint RFD trials were 
published more recently) could have additionally influenced the outcomes in 
favour of the intervention (1 of 6 placebo-controlled, but 2 of 4 steroid injec-
tion controlled trials used a pulsed RFD technique). 
The number of included patients in placebo controlled facet joint RFD trials 
was ≤80, in steroid injection controlled trials (except for one trial) 80-120. 
The sacroiliac RFD trials were even smaller (28/51 patients). The small sam-
ple sizes might be adequately powered to detect considerable differences in 
the primary outcome (e.g., VAS differences for pain), but not for smaller ef-
fects or rare events (e.g., complications). 
Relevance of the outcomes assessed  
to the potential patient-relevant benefits  
All chosen and reported outcomes are patient-relevant. From a single patient, 
but also social perspective implications of the ability to work would have been 
of high interest, but haven’t been reported in a single trial. (Costs and poten-
tially adverse events-producing) Medication (analgetics) has been addressed in 
some of the studies, but has not been considered in this review (e.g., achieved 
reduction).  
For reliable statements on effectiveness, long-term data would be essential to 
determine the mean period of the effect, which is assumed to be not perma-
nent due to nerve recovery. These data should include outcomes like alterna-
tive (more invasive) therapies prevented (e.g., SI joint fusion). RCTs might 
not be able to provide the proposed long-term data, therefore prospective reg-
istries might be necessary to determine these effects.  
insgesamt basieren  
die Effektschätzer  
auf einem geringen 
Evidenzlevel, da 
- die eingeschlossenen 
Studien meist ein 
hohes Biasrisiko 
aufweisen (z. B. nicht 
mögliche Verblindung 
bei Injektionstherapie 
mit potentiellen Folgen 
für ausschließlich durch 
PatientInnenangaben 
erhobene Ergebnisse) 
- die eingeschlossenen 
Studien geringe 
Stichprobenumfänge 
aufweisen 
fehlende Daten  
zu Arbeitsfähigkeit; 
Medikation könnte auch 
von Gesundheitssystem-
interesse sein 
Wirkungsdauer oder 
auch Verhinderung 
anderer Interventionen 
nur in Langzeit-
beobachtungen  
(z. B. Registern) möglich 
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Factors that may influence the external validity 
The two RCTs on RFD for sacroiliac joint pain used a “cooled radiofrequency 
denervation” method (with temperatures from 60 to 80° C and durations from 
90 to 150 seconds). In the RCTs on RFD for facet joint pain, an even greater 
heterogeneity can be observed. Continuous or pulsed RFD methods (40-85° C, 
60-120s) were applied (see Table 8-1). Different techniques result in different 
lesions and ongoing research focuses on these variable effects (see list of on-
going trials Table A-7 and Table A-8). It seems that (like in dose-finding stud-
ies of pharmaceuticals) the optimal “dose” of RFD is still under examination.  
The patient population varied between studies, especially with regard to the 
duration of preceding pain (>3 months up to >2 years). These different lev-
els of ‘chronicity’ could have an impact on the study results. 
Table 8-1: Overview of RFD techniques, used in included RCTs 
Author, year 
Gallagher, 
1994 [31] 
Leclaire,  
2001 [32] 
Nath,  
2008 [30] 
Tekin,  
2007 [5] 
Van Kleef, 
1999 [6] 
Van Wijk, 
2005 [29] 
comparison facet RFD vs. placebo 
intervention NR 
(continuous) 
NR 
(continuous) 
NR 
(continuous) 
continuous RFD/ 
pulsed RFD 
NR 
(continuous) 
NR 
(continuous) 
temperature 80° C  80° C  85° C 80° C/42° C 80° C 80° C 
duration 90 seconds 90 seconds 60 seconds 90 seconds/ 
4 minutes 
60 seconds 60 seconds 
 
Author, year Civelek, 2012 [23] Duger, 2012 [33] Hashemi, 2014 [2] Lakemeier, 2013 [24] 
comparison facet RFD vs. steroid injection 
intervention NR (continuous) pulsed RFD pulsed RFD NR (continuous) 
temperature 80° C 40° C <42° C 80° C 
duration 120 seconds 6 minutes 120 seconds 90 seconds 
 
Author, year Kroll, 2008 [34] Moon, 2013 [35] Sanders, 1999 [36] 
comparison different RFD methods 
intervention continuous RFD/pulsed RFD NR (continuous) NR (continuous) 
temperature 80° C/42° C 80° C  NR 
duration 75 seconds/120 seconds  90 seconds 60 seconds 
 
Author, year Cohen, 2008 [25] Patel, 2012 [4] 
comparison SI RFD vs. placebo 
intervention cooled RFD cooled RFD 
temperature 80° C 60° C 
duration 90 seconds 150 seconds 
SI sacroiliac, RFD radiofrequency denervation, NR not reported 
Übertragbarkeit der 
Ergebnisse potenziell 
eingeschränkt durch: 
 
- Unterschiede in den 
verwendeten RFD 
Methoden 
- heterogene  
PatientInnenpopulation 
(v. a. Schmerzdauer) 
Discussion 
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Applicability of study results to the proposed clinical situation 
Some of the study authors (e.g., [32]) clearly state that the careful patient se-
lection is essential for the success of the intervention. Gallagher [31] reported 
back in 1994 that RFD should “be reserved for those reporting a clear tem-
porary improvement from local anaesthetic” (based on the observation that 
1/3 of the patients were not helped by facet joint injection). Based on availa-
ble study results (and hypotheses from subgroup analyses), it could be pos-
sible to define further selection criteria in the future. 
Results from facet joint RFD studies cannot be adopted one-to-one to SI joint 
RFD. Facet joints are pairs of small joints that are situated at each vertebral 
level in the back of the spine. Sacroiliac joints are located in the pelvis (be-
tween the sacrum and ilium). Each facet joint is connected to two medial 
branch nerves that may carry pain signals to the brain, whereas lateral branch 
nerves carry (pain) signals from SI joints to the brain [9]. Therefore, two dif-
ferent types of RFD have to be distinguished: medial (facet joints) and lateral 
(sacroiliac joints) branch neurotomy. Lumbar facet joint innervation patterns 
are well-known, whereas the sensory innervation of the sacroiliac joint has not 
yet been as definitively defined. Variations of sensory innervation can occur 
[7]. To address this uncertainty, the cooled RFD technique aims at causing 
‘bigger’ (and more) lesions5 than used in conventional facet joint RFD. 
Patients with joint pain due to acute trauma, fracture, malignancy, and in-
flammatory disease were excluded from this review. Therefore, no conclusions 
can be drawn on the effectiveness of RFD in these circumstances. An orient-
ing search in PubMed (see Literature search strategies in the Appendix) for 
SI-RFD in patients with pseudoarthrosis, tumors/cancers, rheumatoid arthri-
tis/spondyloarthropathies (as suggested as potential other indications by the 
submitting hospital) revealed 1 relevant trial (conducted in China, published 
in 2014) [38]. This RCT compared sacroiliac joint RFD (cooled RFD under 
CT-guidance) with a pharmaceutical therapy (celecoxib) in patients with an-
kylosing spondylitis (M. Bechterew; 82 vs. 73 patients). In an observation pe-
riod of up to 24 weeks, they observed a significant pain reduction in favour of 
the RFD intervention and significant less epigastric pain, nausea, diarrhea 
(etc.) than with the nonsteroidal antirheumatic therapy. No severe adverse 
events were reported, but haemorrhages and infections occurred in 6% and 
4% of RFD patients at the treatment site. At least based on this single trial re-
sult, it can be assumed that there might be selected patient populations which 
could benefit from the treatment in the future. 
Evidence gaps  
Neither for RFD in facet joints nor for RFD in sacroiliac joints, long-term 
data (>12 months) is available. Due to crossover, the situation is worst for 
RFD in SI joints, for which no group comparisons >3 months are available. 
Due to the natural course of the disease (chronic/recurrent) and the nature 
of the intervention (non-permanent due to the recovery of nerves) and the 
estimated high number of potentially benefitting patients (common disease), 
long-term data will be essential, not only to estimate the anticipated effect 
for single patients, but also to estimate the effect on the public health level. 
These data will not be obtained by placebo-controlled trials, as “doing noth-
                                                             
5 Online information provided by the manufacturer: 
http://www.halyardhealth.com/solutions/pain-management/chronic-pain-
solutions/sinergy.aspx 
aufgrund der 
Beobachtungen von 
„Non-Respondern”  
wird sorgfältige 
PatientInnenselektion 
seit den 1990er Jahren 
diskutiert 
Ergebnisse der 
Facettengelenks-RFD 
nicht 1:1 auf  
Iliosakralgelenks-RFD 
übertragbar  
(andere anatomische 
Gegebenheiten,  
andere RFD Technik) 
PatientInnen mit 
Schmerzen aufgrund 
von Tumoren, 
rheumatischen 
Erkrankungen etc. 
wurden in diesem 
Review nicht 
berücksichtigt; daher 
keine Aussagen über die 
Wirksamkeit möglich 
 
orientierende Suche nach 
potentiell relevanten 
RCTs identifizierte eine 
Studie mit Iliosakral-RFD 
bei M. Bechterew 
PatientInnen 
Identifizierte 
Evidenzlücken: 
 
v. a. keine 
Langzeitergebnisse 
verfügbar  
(für Iliosakralgelenke 
lediglich nur bis  
3 Monate) 
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ing” will not be tolerated by pain-troubled patients. But as far as the superi-
ority of RFD over the standard treatment (from conservative (steroid injec-
tions, analgetics, ...) to surgical (joint fusion) interventions) is not finally prov-
en, (further or in case of the SI RFD new) direct comparisons will be needed. 
Upcoming evidence 
We identified 2 ongoing RCTs on lumbar facet joint pain comparing conven-
tional and cooled RFD (NCT02478437) and RFD with 80 vs. 90° C (NCT-
02148003) that will be completed Feb 2016-June 2017. The two ‘ongoing’ RCTs 
on sacroiliac joint pain (estimated completion date Dec. 2013-March 2015) 
compare RFD vs. a sham intervention (NCT01726608) and two different RFD 
methods (NCT02382289). 
 
Limitations 
We did not repeat the whole literature search and the selection process of the 
Cochrane Review. We therefore have to be confident that no relevant trial 
(up to 2014) had been missed. 
In line with the Cochrane Review, we did not include other study designs 
than randomised controlled trials. Therefore, safety outcomes should be han-
dled with care. Observational data might have added complications that can-
not be observed in small RCTs.  
Some of the meta-analyses (conducted by Cochrane Review’s authors or based 
on own calculations) are insufficiently sound due to study dependencies, small 
number of studies, or even single studies. We aimed at providing them for the 
sake of completeness. 
 
 
Ausblick: 
3 der 4 laufenden RCTs 
zu Vergleichen 
 
unterschiedlicher RFD 
Techniken 
mögliche Limitationen 
unserer Arbeit: 
- ‚Vertrauen’ in 
Literatursuche/ 
-auswahl der Cochrane 
Review AutorInnen 
(bis 2014) 
- RCTs könnten in 
Sicherheitsfragen 
seltene Ereignisse 
übersehen 
- z. T. fragwürdige 
Metaanalysen 
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9 Recommendation 
In Table 9-1 the scheme for recommendations is displayed and the accord-
ing choice is highlighted. 
Table 9-1: Evidence based recommendation:  
 The inclusion in the catalogue of benefits is recommended.  
 The inclusion in the catalogue of benefits is recommended with restrictions. 
X The inclusion in the catalogue of benefits is currently not recommended. 
 The inclusion in the catalogue of benefits is not recommended. 
 
Reasoning: 
The current evidence is not sufficient to prove that the assessed technology, 
radiofrequency denervation [in adult patients with chronic (>3 months, fac-
et or sacroiliac joint-) low back pain who had a positive response to diagnos-
tic block], is more effective than, and as safe as, the comparator(s) (placebo/ 
sham intervention or conventional treatment). New study results will influ-
ence the effect estimate considerably. 
The re-evaluation is recommended in 2019. 
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Appendix 
Evidence tables of individual studies included for clinical effectiveness and safety 
Table A-1: Facet joint: Radiofrequency denervation vs. placebo treatment: Results from randomised controlled trials 
Author, year Gallagher, 1994 [31] Leclaire, 2001 [32] Nath, 2008 [30] Tekin, 2007 [5] Van Kleef, 1999 [6] Van Wijk, 2005 [29] 
Country UK Canada Sweden Turkey Netherlands Netherlands 
Sponsor NR academic no industry funding NR national funding national funding 
Study design RCT RCT RCT RCT RCT RCT 
Number of pts 41 (24 vs. 17) 70 (36 vs. 34) 40 (20 vs. 20) 60 (20 vs. 20 vs. 20) 31 (15 vs. 16) 81 (40 vs. 41) 
Intervention Facet joint denervation: after 
anaestetizing the area with 
lignocaine 2% 0.5 mL,  
RF lesion was made at 80° C 
for 90 seconds 
group A: good response to 
diagnostic block + 
denervation (n=18) 
group B: equivocal response 
to diagnostic block + 
denervation (n=6) 
Radiofrequency facet 
joint denervation at a 
minimum of 2 levels 
to medial branch of 
distal portion of spinal 
posterior rami nerve 
at 80° C for  
90 seconds (n=36) 
RF denervation of 
lumbar facet joint for 
60 seconds at 85° C 
(n=20) 
Conventional 
radiofrequency (CRF) 
denervation group: 
continuous RF lesions to 
medial branch at 80° C for 
90 seconds at level L1 to L3 
or L3 to L5 (n=20) 
Pulsed radiofrequency 
(PRF) denervation group: 
two Hertz PRF waves were 
applied for 4 minutes (45 V) 
at 42° C (n=20) 
60-second 
radiofrequency lesion 
of 80° C of the medial 
branch of the 
posterior primary 
ramus of the 
segmental nerves L3-
L5 on one or both 
sides (n=15) 
60-second RF lesion at 
80° C of dorsal ramus 
medial branches of 
relevant facet joints 
(n=40) 
Comparator Nerves to joints were 
identified by stimulation, 
local anaesthetic was injected 
in the usual way, but no heat 
lesion was made 
group C: good response to 
diagnostic block + placebo 
(n=12) 
group D: equivocal response 
to diagnostic block + placebo 
(n=5) 
Same procedure as in 
experiment group, 
except that 
temperature of 
electrode tip was not 
raised but was 
maintained at 37° C 
(n=34) 
Identical to 
intervention group, 
except no current 
was used and 
electrode tip 
remained at body 
temperature  
(n=20) 
Control group (C): 
Electrodes and 
thermocouple probes were 
positioned similarly without 
switching on RF current; 
only bupivacaine 0.5%  
0.3 mL was injected  
(n=20) 
Identical procedure as 
in the intervention 
group, but without RF 
current  
(n=16) 
Identical procedure as 
in the intervention 
group, without 
switching on RF 
current  
(n=41) 
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Author, year Gallagher, 1994 [31] Leclaire, 2001 [32] Nath, 2008 [30] Tekin, 2007 [5] Van Kleef, 1999 [6] Van Wijk, 2005 [29] 
Inclusion criteria 25 to 55 years of age; back 
pain >3 months; ≥4 of the 
following symptoms: 
tenderness on palpation, 
more pain on extension than 
on flexion, pain on rotation of 
the spine, referred pain (above 
the knee), pain exacerbated 
by exercise and relieved by 
rest, pain exacerbated by 
sitting or standing, pain not 
exacerbated by coughing or 
sneezing, radiological 
evidence of facet joint 
degeneration or predisposing 
factors (such as loss of disc 
height or spondylolisthesis at 
the painful level) 
18 to 65 years of age; 
low back pain >3 
months; significant 
relief of low back 
pain for ≥24 hours 
during week after 
intraarticular facet 
injections under 
fluroscopy using 
Omnipaque 
Adult participants; 
continuous low back 
pain ≥2 years; no 
response to previous 
treatment; ≥80% 
relief of pain 
following controlled 
medial branch blocks 
>17 years of age; the 
following symptoms for >6 
months: continuous low 
back pain with or without 
radiating into the upper leg, 
with focal tenderness over 
the facet joints, pain on 
hyperextension, no finding 
of obvious neurologic 
defect, no indication for 
low back surgery, no 
radicular syndrome, 
unresponsiveness to 
traditional conservative 
treatments; >50% pain 
relief on VAS to diagnostic 
medial branch block 
20 to 60 years of age; 
chronic low back pain 
>12 months; initial 
mean VAS score >4 or 
VAS high score >7; 
conservative therapy 
attempted without 
success; absence of 
any neurological 
deficit by routine 
neurological 
examination; ≥50% 
pain relief after 
diagnotsic dorsal 
ramus nerve block 
with local anaesthetic 
solution 
>17 years of age; 
continuous low back 
pain with or without 
radiating pain into the 
upper leg >6 months 
with focal tenderness 
over the facet joints; 
no radicular syndrome 
(i.e., no sensory or 
motor deficits, no 
positive straight leg 
raising test); no 
indication for low back 
surgery; ≥50% pain 
reduction on standard 
VAS applied 30 minutes 
after diagnostic block 
of lumbar facet joints 
Exclusion criteria Previous back operations; 
neurological signs of nerve 
root compression in the lower 
limbs; patients with major 
mental illness or severe 
personality disorder;  
pending compensation claims; 
general ill health 
Allergy to local 
anaesthetic; blood 
coagulation disorder; 
cardiac pace-maker; 
sciatic pain with 
neurological deficit; 
low back pain not 
related to mechanical 
disorder; low back 
surgery; concomitant 
medical illness likely 
to compromise ability 
to participate 
Pregnancy; 
coagulopathy; 
malignancy; 
infections; mental 
handicap; psychiatric 
disorder; motor 
deficit or any other 
indication for surgical 
treatment; patients 
who lived too far 
away to be able to 
participate 
Prior RF treatment; 
coagulation disturbances; 
allergy to radiopaque 
contrast media or local 
anaesthetics; malignancy; 
mental handicap or 
psychiatric condition 
precluding adequate 
communication; language 
problems; pregnancy 
Previous back surgery; 
known specific cause 
of low back pain (i.e., 
signs of herniation, 
spondylolisthesis, 
spondylosis 
ankylopoetica, spinal 
stenosis, extensive 
multilevel spondylosis, 
malignancy, infection, 
or trauma);  
diabetes mellitus,  
>1 pain syndrome 
Prior RF treatment; 
coagulation 
disturbances; allergies 
for radiopaque contrast 
local anaesthetics; 
malignancy;  
mental handicap or 
psychiatric condition 
precluding adaequate 
communication; 
language problems; 
pregnancy 
Mean age of patients, 
yrs (SD)  
NR 46.7 (9.3) vs.  
46.4 (9.8) 
56 (range 36-79) vs. 
53 (range 37-76) 
60.5 (8.5) (CRF) vs.  
59.6 (7.7) (PRF) vs.  
57.9 (9.3) (C) 
46.6 (7.4) vs.  
41.4 (7.5) 
46.9 (11.5) vs.  
48.1 (12.6) 
Sex (% female) NR 66.7 vs. 61.8 70 vs. 55 55 (CRF) vs. 60 (PRF) vs.  
55 (C) 
66.7 vs. 62.5 75.0 vs. 68.3 
Mean duration of 
symptoms, months (SD) 
NR NR 132 (range 24-324) vs. 
144 (range 24-612) 
37.5 (12.4) (CRF) vs.  
35.1 (12.0) (PRF) vs.  
32.8 (11.2) (C) 
26 (range 12-120) vs. 
48 (range 12-192) 
duration of pain, %: 
  ≤2 yrs: 22.5 vs. 22.0 
  2-5 yrs: 25.0 vs. 29.3 
  ≥5 yrs: 52.5 vs. 48.8 
Follow-up (months) 6 3 6 12 12 12 
Loss to follow-up, n (%) NR 1 (2.8) vs. 3 (8.8) 0 (0) 0 (0) 1 (3.1) 0 (0) 
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Author, year Gallagher, 1994 [31] Leclaire, 2001 [32] Nath, 2008 [30] Tekin, 2007 [5] Van Kleef, 1999 [6] Van Wijk, 2005 [29] 
Outcomes 
Efficacy 
Pain intensity  Change in VAS score: 
  at 1 month: -17 (A) vs.  
+13 (B) vs. -13 (C) vs. -12 (D), 
s. diff. between groups A and C 
  at 6 months: -7 (A) vs.  
+5 (B) vs. -3 (C) vs. -17 (D),  
s. diff. between groups A and C 
Change in McGill Pain 
Questionnaire scores: 
  at 1 month: -3 (A) vs.  
+4 (B) vs. -2 (C) vs. -5 (D),  
s. diff. between groups A and C 
  at 6 months: 0 (A) vs.  
0 (B) vs. -1 (C) vs. -3 (D) 
Change in VAS score: 
  at 4 weeks:  
-3.6 vs. +0.6, n.s. 
  at 12 weeks:  
+0.5 vs. -7.2, n.s. 
Change in VAS score:  
Back pain: 
   at 6 months:  
-2.1 vs. -0.7; n.s. 
Generalised pain:  
  at 6 months:  
-1.9 vs. -0.4, s.s. 
Change in VAS score:  
  post procedure:  
-4.2 (CRF) vs. -3.8 (PRF)  
vs. -2.5 (C),  
s. diff. between CRF/PRF 
groups and control group 
  at 6 months: -4.2 (CRF) 
vs. -3.7 (PRF) vs. -3.7 (C),  
s. diff. between CRF group 
and PRF/control groups 
  at 12 months: -4.1 (CRF) 
vs. -3.1 (PRF) vs. -2.9 (C),  
s. diff. between CRF group 
and PRF/control groups 
Change in VAS score:  
  at 8 weeks:  
-2.37 vs. -0.43,  
s.s. 
Change in VAS score:  
Back pain: 
  at 3 months:  
-2.1 vs. -1.6, n.s. 
Functional status NR Change in ODI score: 
  at 4 weeks:  
-2.7 vs. -2.1, n.s. 
  at 12 weeks:  
-4.7 vs. -2.7, n.s. 
Change in Roland-
Morris Questionnaire 
(RMQ) score: 
  at 4 weeks: -8.4 vs.  
-2.2, n.s. (p=0.05) 
  at 12 weeks:  
-9.8 vs. -7.2, n.s. 
NR6 Change in ODI score: 
  post procedure:  
-13.6 (CRF) vs. -15 (PRF) vs. 
-9.6 (C), s. diff. between 
CRF/PRF groups and 
control group 
  at 6 months: -14.1 (CRF) 
vs. –14.1 (PRF) vs. -11.2 (C), 
s. diff. between CRF/PRF 
groups and control group 
  at 12 months:  
-11.2 (CRF) vs. -10.9 (PRF) 
vs. -6.5 (C), s. diff. between 
CRF/PRF groups and 
control group 
Change in ODI score: 
  at 8 weeks: -11.07 
vs. +1.69, s.s. 7: 
Change in 
COOP/WONCA chart 
  at 8 weeks:  
-3.13 vs. -1.62, n.s. 
Mean change in 
physical activities: 
  at 3 months:  
+1.5 vs. +0.9, n.s. 
Global improvement NR NR Change in subjective 
global assessment  
(6-point scale):  
  at 6 months:  
-1.1 vs. -0.3, s.s. 
NR Change in global 
perceived effect8: 
  at 8 weeks:  
+1.33 vs. +0.37, s.s. 
Change in global 
perceived effect on 
back pain, %: 
  at 3 months:  
≥50% pain relief:  
61.5 vs. 39.0, s.s. 
                                                             
6 only specific variables for back movement and hip movement provided; no overall score 
7 Dartmouth COOP Functional Health Assessment Charts/World Organisation of Primary Care Physicians (WONCA) 
8 Global perceived effect was scored by the patient on a 7-point scale (ranging from much worse, -3; to 0, no change; to total pain relief, +3) 
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Author, year Gallagher, 1994 [31] Leclaire, 2001 [32] Nath, 2008 [30] Tekin, 2007 [5] Van Kleef, 1999 [6] Van Wijk, 2005 [29] 
Health-related quality 
of life 
NR NR NR9 NR NR s. diff. only in 
parameter “vitality” 
(no total score of  
SF-36 provided) 
Ability to work NR NR NR NR NR NR 
Satisfaction with 
treatment 
NR NR NR Patient satisfaction was 
lower in control group than 
other groups, and highest 
in CRF group (s.s.) 
NR NR 
Safety  
Complications no adverse effects  
no evidence of any nerve root 
anaesthesia or damage 
no complications  no complications no complications  no complications  no significant 
differences in 
occurrence of 
treatment-related pain 
and subjective sensory 
or motor changes 
Abbreviations: NR not reported; n.s. not significant; ODI Oswestry Disability Index; RF radiofrequency; s.s. statistically significant; VAS visual analogue scale; yrs years;  
CRF conventional RFD, PRF pulsed RFD 
  
                                                             
9 various quality of life variables provided, but no overall score 
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Table A-2: Facet joint: Radiofrequency denervation vs. steroid injection: Results from randomised controlled trials 
Author, year Civelek, 2012 [23] Duger, 2012 [33] Hashemi, 2014 [2] Lakemeier, 2013 [24] 
Country Turkey Turkey Iran Germany 
Sponsor NR NR NR no funding 
Study design RCT RCT RCT RCT 
Number of pts 100 (50 vs. 50) 120 (40 vs. 40 vs. 40) 80 (40 vs. 40) 56 (27 vs. 29) 
Intervention Facet joint radiofrequency (FJRF) 
denervation at 80°C for 120 seconds 
(n=50) 
RF denervation group (group R): 
localisation of RF electrode in the facet 
joint causing pain was determined by 
sensorial stimulus and C-armed scope 
device. Pulsed RF thermocoagulation  
for 6 minutes at 40°C with RF lesion 
generator (n=40) 
Pulsed radiofrequency (n=40) Radiofrequency denervation: curved RF 
needles with 100-mm active tips were 
placed at the site of the dorsal ramus 
medial branch of the relevant L3/L4-L5/ 
S1 LFJs, 1mL of 0.5% bupivacaine was 
injected, the RF probe was then inserted 
into the cannula and lesion at a 
temperature of 80° C for 90 seconds 
using an RF generator (n=27) 
Comparator Facet joint injection (FJI) with 
medial branch block of posterior 
primary ramus with 1 cc of 
methylprednisolone acetate (40 
mg) (diluted with 1 cc SF) 
combined with 2 cc bupivacaine 
hydrochloride (diluted with 2 cc SF) 
(n=50) 
Injection group (group B): after C-arm 
scope guided determination of injection 
point, injection of 1.5mL of 20mg methyl-
prednisolone acetate mixed with 5mg 
bupivacaine into the facet joint (n=40) 
RF denervation and injection group 
(group RB): localisation of RF electrode 
in the facet joint causing pain was 
determined by sensorial stimulus and  
C-armed scope device. Pulsed RF thermo-
coagulation for 6 minutes at 40°C and 
injection of 1.5 ml mixture of 20 mg 
methylprednisolone acetate and 5 mg 
bupivacaine at the same localization 
(n=40) 
Injection by steroids (1 mL 
(40mg) triamcinolone) and 
0.5mL bupivacaine 0.5%  
(n=40) 
Intraarticular injection of steroids: 
same setting was used for LJF 
infiltrations and RF denervation; the 
RF probe was inserted into the cannula 
and the denervation process (80° C for 
90 seconds) was begun, but the 
electrodes were not connected to the 
pain generator device (n=29) 
Inclusion criteria Chronic and debilitating low back 
pain leading to diagnosis of lumbar 
facet syndrome; not responding to 
conservative treatment for up to 6 
weeks, including various analgesics 
and physical therapy and additional 
pain relief after FJI for participants 
with FJRF; symptoms of facet syn-
drome include local tenderness over 
1 or more FJs, back pain aggravated 
by hyperextension and rotation, 
morning stiffness or pain increasing 
in the morning and hip and buttock 
pain of a non-radicular distribution 
18 to 60 years of age; single-sided low 
back pain arising from facet joint; 
complaints longer than 6 months, limited 
functions and daily life; presented with  
at least 2 of the 4 symptoms of facet 
syndrome (back pain aggravation by 
hyperextension and rotation, morning 
stiffness or pain increasing in the 
morning, local tenderness over one or 
more facet joints and hip and buttock 
pain of a nonradicular distribution) 
>18 years of age; 
spondylolisthesis grade I in MRI 
at 1 single level (2 adjacent 
vertebrae and 1 disc); chronic low 
back pain >6 months; supra-
vertebral facet tenderness; pain in 
hyperextension; minimum NRS 
score of 4 (moderate to severe 
pain) and positive diagnostic 
medial branch block test 
≥18 years of age; lumbar facet joint 
(LFJ)-related low back pain ≥24 months; 
ability to understand study protocol 
and to provide voluntary written 
informed consent and participate in 
outcome measurements; a benefit in 
pain reduction ≥50% after test injection 
of local anaesthetics into the L3/L4-L5/S1 
LFJ; MRI-proven LFJ osteoarthritis and 
hypertrophy in the L3/L4-L5/S1 
segments 
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Author, year Civelek, 2012 [23] Duger, 2012 [33] Hashemi, 2014 [2] Lakemeier, 2013 [24] 
Exclusion criteria Radicular pain, neurogenic 
claudication and neurological 
deficits; acute or uncontrolled 
medical illness; known history of 
adverse reactions to local 
anaesthetics, pregnancy or 
lactation 
Coagulation defect, major depression  
and uncontrolled psychiatric disorder, 
pregnancy or lactation, respiratory or 
cardiac problems in prone position, opioid 
treatment during the previous month, 
undergoing surgical procedure at the 
same site, infection at the procedure site, 
disc-related radicular symptoms; patients 
not accepting the procedure and not 
giving informed consent 
Radicular pain; neurologic deficit; 
indication for surgery (neurologic 
deficit and urinary inconsistent); 
stenosis of the spinal canal; 
spondylolysis; positive straight 
leg raising test; suppressed reflex; 
known psychiatric disease; spinal 
deformity; neoplastic or 
infectious disease 
Lack of positive response to L3/L4-L5/S1 
test infiltration; history of osteoporosis 
or malignancies; allergies to local 
anaesthetics; pregnancy or lactation; 
lumbar spinal stenosis or spinal 
instability; vertebral fracture; 
symptomatic radiculopathy; 
uncontrolled psychiatric disorder; 
uncontrolled medical illness; condition 
that could interfere with interpretation 
of outcome assessments; history of 
adverse reactions to corticosteroids 
Mean age of patients,  
yrs (SD)  
51.8 (17.0) vs. 56.5 (17.7) 50.2 (12.1) (R) vs.  
50.1 (12.3) (B) vs. 51.2 (11.9) (RB) 
64.3 (13.3) vs. 63.9 (11.5) 57.6 (12.8) vs. 56.3 (10.8) 
Sex (% female) 70.0 vs. 70.8 53.3 (R) vs. 56.7 (B) vs. 56.7 (RB)a 52.5 vs. 55.0 34.6 vs. 38.5 
Mean duration of 
symptoms, months (SD) 
18.9 (12.9) vs. 18.7 (12.3) 10.7 (5.2) (R) vs. 11.3 (5.1) (B) vs.  
11.0 (5.0) (RB) 
3.4 (2.3) vs. 3.8 (2.5) NR 
Follow-up (months) 12 12 6 6 
Loss to follow-up, n (%) 0 (0) NR 1 (2.5) vs. 1 (2.5) 1 (4) vs. 3 (10) 
Outcomes 
Efficacy 
Pain intensity  Change in VNS score: 
  at 1 month: -6.0 vs. -5.1, s.s 
  at 6 months: -5.7 vs. -4.1, s.s. 
  at 12 months: -5.6 vs. -3.6, s.s. 
Change in VAS score: 
  at 1 month: -4.3 (R) vs. -1.7 (B) vs.  
-4.2 (RB), s. diff. btw. R and B,  
and btw. RB and B 
  at 6 months: -4.2 (R) vs. -0.6 (B) vs.  
-4.3 (RB), s. diff. btw. R and B,  
and btw. RB and B 
  at 12 months: -3.3 (R) vs. -0.1 (B)  
vs. -3.4 (RB), s. diff. btw. R and B,  
and btw. RB and B 
Change in NRS score: 
  at 6 months: -5 (PRF group), s. 
diff. between PRF and steroid 
group at 12 weeks and 6 months, 
n.s. at 6 weeks 
Change in VAS score: 
  at 6 months: -1.9 vs. -1.6, n.s. 
Functional status NR NR Change in ODI score: 
  at 6 months: -56.3% (PRF 
group), s. diff. between PRF and 
steroid group at 12 weeks and  
6 months, n.s. at 6 weeks 
Change in ODI score: 
  at 6 months: -12.8 vs. -5.7, n.s. 
Change in RMQ score: 
  at 6 months: -3.7 vs. -4.2, n.s. 
Global improvement NR NR NR NR 
Health-related quality  
of life 
Change in EQ-5D score:  
  at 1 month: -8.2 vs. -8.7, n.s. 
  at 6 months: -7.3 vs. -7.5, n.s. 
  at 12 months: -7.1 vs. -6.7, n.s. 
NR NR NR 
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Author, year Civelek, 2012 [23] Duger, 2012 [33] Hashemi, 2014 [2] Lakemeier, 2013 [24] 
Ability to work NR NR NR NR 
Satisfaction with 
treatment 
There was no significant difference 
in the 1st and 6th month follow-ups, 
however there was a significant 
difference respect to 12 month 
NASS patients’ satisfaction scores10 
All the values except those obtained at 
day 2 and week 1 were higher in group R 
when compared to group B; in group RB, 
early satisfaction values (day 1, day 2, 
week 1) were higher compared to group 
R; in group RB, all satisfaction values 
except at day 2 and week 1 were higher 
compared to group B  
Patient satisfaction was 
significantly higher in PRF group 
at 12 weeks and 6 months 
compared to steroid group 
NR 
Safety 
Complications no infections or new motor or 
sensory deficits  
rare complaints of small superficial 
burns after RFD 
increase in severity of low back  
pain in 2 RFD pts (4%) in the early 
follow-up period 
no complications  NR no major adverse events  
Abbreviations: FJI Facet joint injection, FJRF Facet joint radiofrequency, NASS North American Spine Society patient satisfaction questionnaire; NRS numeric rating scale; NR not reported; 
n.s. not significant; ODI Oswestry Disability Index; RF radiofrequency; RMQ Roland-Morris Questionnaire; s.s. statistically significant; VAS visual analogue scale; VNS visual numeric pain scale; 
yrs years 
a instead of 40 pts per group only 30 each are described in the demographic data table. An email request to the author (8.2.2016) remained without reply. 
 
Table A-3: Facet joint: Radiofrequency denervation vs. other treatment (other RFD method): Results from randomised controlled trials 
Author, year Kroll, 2008 [34] Moon, 2013 [35] Sanders, 1999 [36] 
Country USA Korea Netherlands 
Sponsor NR no industry funding NR 
Study design RCT RCT RCT 
Number of pts 26 (13 vs. 13) 82 (41 vs. 41) 34 (17 vs. 17) 
Intervention Continuous RF group (CRF): continuous RF 
thermocoagulation lesioning performed at  
80° C for 75 seconds (n=13) 
Distal approach group (D): fluoroscopic distal 
approach was used for L1 to L4 medial branches 
(n=41) 
Percutaneous intra-articular facet denervation 
(PIFD): after injection of 1ml lidocaine 2%, 3 RF 
lesions (60 seconds) were made in the articular 
cavity, central, rostral, and caudal of the facet 
joint (n=17) 
 
                                                             
10 NASS Score: 1=fully meeting of patient’s expectations, 2=less improvement than the hoped for result but the patient would undergo the same procedure again,  
3=the procedure helped but the patient would not undergo again, 4=the same or worse status with respect to pre-operative status 
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Author, year Kroll, 2008 [34] Moon, 2013 [35] Sanders, 1999 [36] 
Comparator Pulsed RF group (PRF): pulsed RF lesioning at  
42° with pulse duration of 20 ms and pulse rate of 
2 Hz for 120 seconds (n=13) 
Tunnel vision approach group (TV): lumbar medial 
branch radiofrequency denervation was performed 
under fluoroscopic guidance in an oblique “tunneled” 
view, as described by Bogduk 2005 (n=41) 
Extra-articular facet denervation (PEFD) 
following the method described by Mehta and 
Sluijter (n=17) 
Inclusion criteria ≥18 years of age; ASA11 physical status I, II and III; 
unilateral or bilateral lumbar back pain for longer 
than 1 month; no radiating symptoms below the 
knee; >50% pain reduction based on mean VAS 
after 2 separate diagnostic medial branch blocks 
with 1.0mL of 0.5% bupivacaine 
>18 years of age; predominantly axial lower back 
pain for ≥3 months; paraspinal tenderness overlying 
the L2 to L4 lumbar facet joints; failure to respond 
to conservative therapy such as physical therapy 
or pharmacotherapy; concordant pain relief of 
>50% after a comparative local anaesthetic block 
with 0.5mL lidocaine 1% (≥1 hour) and 
levobupivacaine hydrochloride 0.5% (≥3 hours)  
at the L1 to L4 medial branches 
Low back pain >6 months; pain exacerbated by 
extension of the lumbar spine, prolonged standing 
or sitting; deep pressure pain over the lumbar facet 
joints and absence of neurological abnormalities; 
no improvement from physical therapy;  
pain intensity on VAS >4;  
≥50% pain relief after diagnostic block 
Exclusion criteria History of previous back surgery; presence of 
neurological deficits; claudication; active 
psychiatric disorder; bleeding disorder; active 
infection; pregnancy; involved in current litigation; 
ongoing workers’ compensation claims;  
disc herniation and spinal stenosis  
(ruled out radiographically)  
Any focal neurological signs or symptoms; 
radiologic evidence of a symptomatic herniated disc; 
severe spinal stenosis or structural lumbar spinal 
deformity; a positive response to previous spinal 
interventions such as sacroiliac joint block or 
epidural steroid injection; discogenic pain verified 
by discography; lumbar spine fusion; untreated 
coagulopathy; concomitant medical or psychiatric 
condition likely to undermine diagnostic workup 
or assessment of treatment response 
Radicular pain (neurological signs of nerve root 
compression); previous back operation(s);  
age <18 years; bleeding disorders; presence of 
prominent functional or non-physiological signs 
Mean age of patients,  
yrs (SD)  
59.5 (11.6) (CRF) vs. 57.0 (8.4) (PRF) 68.6 (13.8) (D) vs. 62.6 (14.5) (TV) 60.9 (18.5) vs. 62.6 (14.6) 
Sex (% female) 46.1 (CRF) vs. 61.5 (PRF) 61.8 (D) vs. 70,6 (TV) 23.5 vs. 29.4 
Mean duration of 
symptoms, months (SD) 
NR 40.8 (40.6) (D) vs. 29.3 (23.9) (TV) NR 
Follow-up (months) 3 6 3 
Loss to follow-up, n (%) 12 (48) vs. 12 (48) 5 (12.2) (D) vs. 6 (14.6) (TV)12 NR 
Outcomes 
Safety 
Complications No adverse events were encountered during CRF 
or PRF lesioning, and no complications were 
documented 3 months post-procedure 
RF-associated complication during the 6-month 
follow-up: 1 (D) vs. 5 (TV) 
(mild, localized pain at the RF lesion site lasting  
<1 month (1 vs 2); new neuropathy-like pain 
lasting >3 months (0 vs 3)) 
No complications or morbidity were observed 
Abbreviations: FJI Facet joint injection, FJRF Facet joint radiofrequency, NASS North American Spine Society patient satisfaction questionnaire; NRS numeric rating scale; NR not reported; 
n.s. not significant; ODI Oswestry Disability Index; RF radiofrequency; RMQ Roland-Morris Questionnaire; s.s. statistically significant; VAS visual analogue scale; VNS visual numeric pain scale; 
yrs years 
                                                             
11 is a five-category physical status classification system adopted by the American Society of Anesthesiologists (ASA) for assessing the fitness of patients before surgery:  
I = healthy person; II = mild systemic disease; III = severe systemic disease 
12 Additionally, 3 patients (1 in the tunnel vision approach group and 2 in the distal approach group) were excluded because of failure in both motor and sensory stimulation at 2 or 
more nerves. 
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Table A-4: Sacroiliac joint Radiofrequency denervation vs. placebo: Results from randomised controlled trials 
Author, year Cohen, 2008 [25] Patel, 2012 [4] 
Country USA USA 
Sponsor academic/Baylis Medical Baylis Medical 
Study design RCT RCT 
Number of pts 28 (14 vs. 14) 51 (34 vs. 17) 
Intervention Cooled RF denervation group received L4-L5 primary dorsal rami and  
S1-S3 lateral branch RF denervation (80°C, 90 seconds) using cooling 
probe technology after local anaesthetic block (n=14) 
RF energy was delivered for 150 seconds at set temperature of 60°C;  
first L5 dorsal ramus was lesioned; after coagulation of L5 dorsal ramus, 
sacral lateral branches of S1, S2 and S3 were targeted (n=34) 
Comparator Control group received local anaesthetic block followed by placebo 
denervation, in which 0.5 ml lidocaine 2% was administered with no 
current (n=14) 
Participants who did not respond to placebo injections crossed over and 
were treated with RF denervation using conventional technology (n=11) 
Same procedure as in experimental group, except that RF energy was not 
delivered. Probe placements, procedure duration, equipment sounds and 
visual indications for participants were identical in both groups  
(n=17) 
Inclusion criteria >18 years of age; axial low back or buttock pain ≥ 6 months; tenderness 
overlying SI joint(s); failure to respond to conservative therapy  
(e.g., physical therapy and pharmacotherapy); long-term (>2 months) 
pain relief with SI joint corticosteroid injections; pain relief ≥ 75% as 
calculated from a 6-hour post-block pain diary after a single  
diagnostic SI joint injection 
>18 years of age; predominantly axial pain below L5 vertebrae; axial pain 
lasting longer than 6 months; three-day average NRS between 4 and 8; 
failure to achieve adequate improvement with comprehensive non-operative 
treatments, including but not limited to activity alteration, non-steroidal 
antiinflammatory drugs, physical and/or manual therapy and fluoro-
scopically guided injections of steroids into SIJ or sacroiliac ligaments; 
other possible sources of low back pain reasonably excluded (by means of 
physical exam, medical history and magnetic resonance imaging/computed 
tomography/X-ray as required), including but not limited to bone fracture, 
hip joint, symptomatic spondylolisthesis, tumour and other regional soft 
tissue structures 
Exclusion criteria Focal neurological signs or symptoms; radiological evidence of 
symptomatic herniated disc; spondyloarthropathy; untreated 
coagulopathy; unstable medical or psychiatric illness that might  
preclude an optimal treatment response 
Beck Depression Inventory score >20; irreversible psychological barriers  
to recovery; spinal pathology that may impede recovery, such as 
spondylolisthesis at L5/S1, or scoliosis; symptomatic moderate or severe 
foraminal or central canal stenosis; systemic infection or localised 
infection at anticipated introducer entry site; concomitant cervical or 
thoracic pain >2/10 on a NRS scale; uncontrolled or acute illness; chronic 
severe conditions such as rheumatoid/inflammatory arthritis; pregnancy; 
active radicular pain; immunosuppression (e.g. AIDS, cancer, diabetes, 
surgery < 3 months before); workers’ compensation, injury litigation or 
disability remuneration; allergy to injectate or medications used during 
procedure; high narcotics usage (> 30 mg morphine daily or equivalent); 
active smokers (termination ≥ 6 months with no smoking during follow-up 
period acceptable with caution);); history of potentially confounding 
intervertebral disc disease or zygapophyseal joint pain 
Mean age of patients, yrs (SD)  51.9 (13.6) vs. 51.8 (13.1) 56 (15) vs. 64 (14) 
Sex (% female) 64 vs. 57 68 vs. 82 
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Author, year Cohen, 2008 [25] Patel, 2012 [4] 
Mean duration of symptoms NR 6-12 months: 18% vs. 6% 
12-24 months: 15% vs. 18% 
>24 months: 65% vs. 77% 
Follow-up (months) 6 (crossover of control group patients after 1 or 3 months) 9 resp. 12 [3] (but crossover of control group patients after 3 months) 
Loss to follow-up, n (%) 0 (0) 0 (0) at 3 months 
Outcomes 
Efficacy 
Pain intensity  Change in NRS scores: 
  at 1 month: -3.7 vs. -0.2, s.s. 
  at 3 months: -3.7 vs. -0.513 
Change in NRS scores: 
  at 1 month: -2.7 vs. -1.7, n.s. 
  at 3 months: -2.4 vs. -0.8, s.s. 
Functional status Change in ODI scores: 
  at 1 month: -16.2 vs. -4.3, s.s. 
  at 3 months: -18.6 vs. -23.913 
Change in ODI scores: 
  at 1 month: -12 vs. -4, s.s. 
  at 3 months: -11 vs. +2, s.s. 
Global improvement Positive GPE14, % (95% CI): 
  at 1 month: 93 (78-100) vs. 21 (2-45), s.s. 
  at 3 months: 83 (59-100) vs. 013 
Positive GPE15, % (95% CI): 
  at 3 months: 47 (29-65) vs. 8 (0-36), s.s. 
Health-related quality of life NR Change in AQoL scores: 
  at 1 month: +0.07 vs. +0.07, n.s. 
  at 3 months:+0.09 vs. +0.02, s.s. 
Ability to work NR NR 
Satisfaction with treatment NR NR 
Safety 
Complications no serious complications (both groups) 
majority of patients: temporary worsening pain (lasting 5-10 days  
after the procedure)  
one RFD patient (1/25 (4%) due to crossover) reported transient 
nonpainful buttock paresthesia that resolved without therapy 
no serious complications (both groups)  
small proportion of subjects: soreness or numbness at the  
introducer sites in the 2 weeks following treatment  
one subject: shingles at the introducer site  
(deemed unrelated to treatment) 
Abbreviations: AQoL Assessment of Quality of Life; GPE Global Perceived Effect; NR not reported; NRS numerical rating pain scale; n.s. not significant; ODI Oswestry Disability Index;  
RF radiofrequency; s.s. statistically significant; VAS visual analogue scale; yrs years 
                                                             
13 Due to crossover of control group, 3-months results are based on only 2 patients in the original placebo group 
14 A positive GPE was defined as an affirmative response to the following 3 questions: 1. My pain has improved/worsened/stayed the same since my last visit; 2. The treatment I received 
improved/did not improve my ability to perform daily activities; 3. I am satisfied/not satisfied with the treatment I received and would recommend it to others. 
15 GPE was measured by having subjects rate their index pain on a 7-item scale; a GPE score was considered positive if the subject rated GPE as „pain has decreased a lot“ or „pain 
is completely gone“ 
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Risk of bias table 
The risk of bias of included studies was assessed by the Cochrane Risk of Bias tool and judged by two researchers. A more detailed description of the criteria used 
to assess the internal validity of the individual study designs can be found in the Cochrane Handbook for Systematic Reviews of Interventions [39].  
Table A-5: Risk of bias – study level (randomised studies) 
Trial 
Adequate generation  
of randomisation 
sequence 
Adequate 
allocation 
concealment 
Blinding 
Selective outcome 
reporting unlikely* 
No other aspects 
which increase the 
risk of bias 
Risk of bias – study 
level Patient 
Treating Physician/ 
follow up examination 
RFA in fact joints vs. placebo 
Gallagher, 1994 [31]  unclear unclear yes unclear/yes unclear noa high 
Leclaire, 2001 [32] yes yes yes unclear/yes unclear yes low 
Nath, 2008 [30] yes yes yes yes/yes unclear no b high 
Tekin, 2007 [5] yes yes yes unclear/yes unclear yes low 
Van Kleef, 1999 [6] yes yes yes yes/yes unclear yes low 
Van Wijk, 2005 [29] yes yes yes yes/yes unclear yes low 
RFA in fact joints vs injection therapy  
Civelek, 2012 [23] yes unclear unclear no/yes unclear yes high 
Duger, 2012 [33] unclear unclear unclear no/unclear unclear no a high 
Hashemi, 2014 [2] yes unclear no no/yes unclear yes high 
Lakemeier, 2013 [24] yes yes yes no/yes unclear yes low 
RFA in SI joints 
Cohen, 2008 [25] yes yes yes unclear/yes yes no b high 
Patel, 2012 [4] yes yes yes no/yes yes yes low 
RFA in fact joints vs. other method of RFA (for safety only) 
Kroll, 2008 [34] yes unclear unclear unclear unclear no c high 
Moon, 2013 [35] unclear unclear unclear unclear/unclear yes yes high 
Sanders, 1999 [36] unclear unclear unclear unclear/unclear unclear noa high 
*This risk was defined as unclear if author’s didn’t explicitly state that a protocol was published before/the study was not registered;  
a number of drop-outs unclear; b baseline characteristics not similar; c high number of drop-outs 
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Applicability tables 
Table A-6a: Summary table characterising the applicability of a body of studies (RFD for facet joint pain) 
Domain Description of applicability of evidence 
Population The patient population (n=679) differed considerably between studies. Patients had suffered from 
back pain for more than 3 months up to at least 2 years. The mean age of included patients ranged 
from 41 to 64 years. The percentage of female participants was more than half of the patients in all, 
but one trial.  
Intervention The RCTs on RFD for facet joint pain applied continuous or pulsed RFD methods (40-85° C, 60-120s). 
The optimal “dose” of RFD seems to be still under examination.  
Comparators 6 trials compared radiofrequency denervation with a placebo/sham treatment, the remaining  
4 studies used steroid injections as comparator. 
Outcomes All outcomes defined as crucial for the decision were reported in the included trials: All trials reported 
pain outcomes (generally measured by the VAS), half of the trials changes in functional status mesured 
by the ODI. 3 trials reported ‘global impovements’ and only 2 assed (generic) health-related quality 
of life. 9 of 10 studies mentioned (at least the non-occurance of) complications, but there seemed  
to be no standardised assessment/documentation. Of the important (not crucial) outcomes, 4 studies 
reported on patient satisfaction, non on the ability to work. There are no data on outcomes at  
>12 months after intervention. 
Setting 3 trials were conducted in Turkey, 2 in the Netherlands, the remaining 5 studies in Canada, Germany, 
Iran, Sweden, and the UK. The steroid injection compared trials were conducted more recently 
(published between 2012 and 2014) than the placebo-controlled trials (1994-2008).  
 
Table A-6b: Summary table characterising the applicability of a body of studies (RFD for sacroiliac joint pain) 
Domain Description of applicability of evidence 
Population The total number of patients was 79. Patients had suffered from low back pain for more than  
6 months and had not achieved adequate improvement after conservative therapies.  
The mean age of patients was 52-64 years. 57-82% of the patients were female. 
Intervention Both RCTs used a “cooled radiofrequency denervation” method (with temperatures from 60 to 80°C 
and durations from 90 to 150 seconds). The optimal “dose” of RFD seems to be still under examination. 
Comparators Both RCTs compared radiofrequency denervation with placebo/sham treatment. 
Outcomes All outcomes defined as crucial for the decision were reported in the included trials: Both trials 
reported pain outcomes (measured by the NRS scores) and changes in functional status mesured by 
the ODI. Both trials also reported the ‘global impovement’ (determined by the same instrument (GPE). 
Only 1 trial asked (generic) health-related quality of life. Both studies described complications (in more 
detail than the facet joint pain studies). None of the studies provided data on the outcomes defined 
as important (not crucial: patient satisfaction, the ability to work). There are no data on outcomes 
at >3 month after intervention. 
Setting On the contrary to the above mentioned trials on RFD for facet joint pain (no north American study), 
both trials on sacroiliac joint pain were conducted in the US (and published 2008-2012).  
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List of ongoing randomised controlled trials 
Table A-7: List of ongoing randomised controlled trials of RFD for facet joint pain  
Identifier/ 
Trial name 
Patient  
population Intervention Comparison 
Primary  
Outcome 
Primary 
completion 
date Sponsor 
NCT02478437 
A Trial of Cooled 
Radiofrequency Ablation of 
Medial Branch Nerves for the 
Treatment of Lumbar Facet 
Syndrome 
18-79 years of age, lumbar facet syndrome pain, 
low back pain >6 months, pain resistant to 
conventional therapy, pain diagram suggesting 
possibility of facet-mediated pain, positive response 
to at least 1 set of diagnostic intra-articular facet 
injections or medial branch blocks 
Conventional radio-
frequency ablation 
(RFA) 
Cooled radio-
frequency ablation 
(CRFA) 
Pain improvement, global pain 
score, McGill Pain Questionnaire 
(MPQ), Pain Anxiety Symptom Scale 
short form (PASS-20), Center for 
Epidemiologic Studies Depression 
short form index (CESD-10) 
June 2017 North-western 
University, 
American Pain 
Society 
NCT02148003 
Effect of the Temperature 
Used in Thermal 
Radiofrequency Ablation 
>18 years of age, low back pain, chronic back pain 
attributed to lumbar facet joints arthropathy, 
adequate response to the diagnostic blocks 
without the use of steroids 
Radio-frequency 
ablation (performed at 
90 degrees Celsius) 
Radio-frequency 
ablation (performed  
at 80 degrees Celsius) 
Assessing a change of pain relief, 
number of repeats of procedure 
February 
2016 
The Cleveland 
Clinic 
 
Table A-8: List of ongoing randomised controlled trials of RFD for sacroiliac pain 
Identifier/ 
Trial name 
Patient  
population Intervention Comparison 
Primary  
Outcome 
Primary 
completion 
date Sponsor 
NCT02382289 
Radiofrequency in Sacroiliac 
Arthropathy;  
Bipolar RF 6 Points Versus 
Monopolar RF at 6 and  
3 Points 
>18 years, chronic sacroiliac joint arthropathy; 
moderate to severe low back pain for >6 months 
with positive Patrick’s and Yeoman’s tests with 
tenderness over the SI joint. Pain is not responding 
to the usual medical treatment. >50% pain relief 
after diagnostic injection with local anesthetic. 
Procedure:  
radio-frequency 
ablation for sacroiliac 
joint arthropathy 
Comparing bipolar RF 
at 6 points with 
monopolar RF at  
3 and 6 points for  
the treatment of  
SI arthropathy 
Patient satisfaction March 2015 King Hamad 
University 
Hospital,  
Bahrain 
NCT01726608 
RFN for SIJ Disease Study16 
18-80 years of age, low back pain >6 months 
duration, >80% reduction in pain following  
each diagnostic, intra-articular block. 
Active radio-frequency 
neurotomy 
Sham radio-frequency 
neurotomy 
Pain intensity, quality of pain, 
health related quality of life, anxiety 
and depression, functional disability, 
health related quality of life and 
quality-adjusted life years, portion 
of patients randomised to sham 
requiring rescue therapy with RFN 
December 
2013 
Barts &  
The London NHS 
Trust 
                                                             
16 Due to the provided study completion date (2013), we contacted the principal investigator (V. Metha) on Feb 28th, but received no answer so far. 
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Additional information:  
List of (registered) completed but unpublished or terminated randomised controlled trials 
Table A-9a: List of completed but unpublished randomised controlled trials (RFD for facet joint pain) 
Identifier/ 
Trial name Patient population Intervention Comparison Primary Outcome 
Primary 
completion date Sponsor 
NCT00476684 
The Effect of 
Radiofrequency-treatment 
on Patients With Facet-joint 
Pain in Cervical- and 
Lumbar-columna17 
20-75 years of age, one-sided neck and  
low back chronic pain, pain durability of 
at least 1 year 
Radio-frequency 
treatment 
Sham neurotomy Reduction in self-reported pain 
intensity 
May 2010 Norwegian 
University of 
Science and 
Technology 
NCT0048415918 
Efficacy and Cost: Benefit 
Ratio of 0, 1, and 2 Medial 
Branch Blocks for Lumbar 
Facet Joint Radiofrequency 
Denervation 
>18 years of age, axial low back pain 
unresponsive to conservative treatment, 
duration of pain >6 months 
Radio-frequency 
denervation of medial 
branches that innervate 
the lumbar facet joints 
Comparison of 3 
different RFD groups 
Cost per successful procedure, 
successful treatment 
January 2009 Johns Hopkins 
University 
 
Table A-9b: List of terminated randomised controlled trials (RFD for sacroiliac pain) 
Identifier/ 
Trial name Patient population Intervention Comparison Primary Outcome 
Primary 
completion date Sponsor 
NCT0115809219 
Trial Comparing Treatment 
With SInergy™ System to 
Conservative Treatment for 
Chronic Sacroiliac Joint Pain 
>18 years of age, predominantly axial pain 
below the L5 vertebrae >75% pain relief 
from 2 separate lateral branch blocks done 
on different days, chronic axial pain lasting 
>six months, no improvement with 
comprehensive non-operative treatments 
Lateral branch 
denervation using the 
SInergy™ System 
(cooled RFD) 
Conservative 
Treatment: physical 
therapy, chiropractic 
care, and medication 
Pain status change for sacroiliac 
region, change in bodily pain and 
physical functioning evaluated using 
SF-36, change in disability evaluated 
using Oswestry Disability Index, 
change in quality of life 
March 2012 Baylis Medical 
Company 
 
                                                             
17 A web search revealed the information that study data has not been published yet. Principal investigator (P. Borchgrevink) was contacted on Feb 28th, but no answer was received 
18 Basic Results are already provided at clinicaltrials.gov. Principal investigator (S.Cohen) contacted on Feb 28th; his answer: “This study has enrolled 160 out of 225 patients.  
It is still ongoing and nothing has been published yet.” 
19 This study has been terminated. E. Ross (principal investigator ) contacted 28.2.2016, his answer: “I believe funding was stopped by the sponsoring company” 
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Literature search strategies 
Search strategy for MEDLINE  
Search Name: Update search (of Cochrane Review) explicitly including the sacroiliac joint 
Database: Ovid MEDLINE(R) <1946 to November Week 3 2015>, Ovid MEDLINE(R) In-Process & Other Non-
Indexed Citations <December 28, 2015>, Ovid MEDLINE(R) Daily Update <November 18, 2015>, Ovid 
OLDMEDLINE(R) <1946 to 1965> 
Search Date: 09.12.2015 
ID Search 
#1 1 ((randomized controlled trial or controlled clinical trial).pt. or randomi#ed.ab. or placebo.ab,ti. or drug 
therapy.fs. or randomly.ab,ti. or trial.ab,ti. or groups.ab,ti.) not (animals not (humans and animals)).sh. 
(3275407) 
#2 dorsalgia.ti,ab. or exp Back Pain/or backache.ti,ab. or (lumbar adj pain).ti,ab. or coccyx.ti,ab. or 
coccydynia.ti,ab. or sciatica.ti,ab. or sciatic neuropathy/or spondylosis.ti,ab. or lumbago.ti,ab. (41368) 
#3 exp Spine/or discitis.ti,ab. or exp Spinal Diseases/or (disc adj degeneration).ti,ab. or (disc adj prolapse).ti,ab. 
or (disc adj herniation).ti,ab. or spinal fusion.sh. or (facet adj joints).ti,ab. or intervertebral disc.sh. or 
postlaminectomy.ti,ab. or arachnoiditis.ti,ab. or (failed adj back).ti,ab. (179612) 
4 2 or 3 (205558) 
5 exp Radio Waves/or exp Pulsed Radiofrequency Treatment/or radiofrequency.mp. or radio frequency.mp. or 
exp Electrocoagulation/or electrocoag$.mp. or thermocoag$.mp. or (neurotom$ or neuroly$).mp. (73259) 
6 1 and 4 and 5 (235) 
7 exp Sacroiliac Joint/(3419) 
8 sacroiliac joint*.mp. (4726) 
9 sacro-iliac joint*.mp. (283) 
10 7 or 8 or 9 (4842) 
11 4 or 10 (207914) 
12 1 and 5 and 11 (243) 
13 12 not 6 (8) 
Total: 8 Hits 
 
 
Additional information: Search strategy for PubMed 
Search Name: Radiofrequenc Denervation for sacroiliac joint pain due to “other indications” 
Search Date: 04.02.2016 
((Sacroiliac Joint[MeSH] OR sacroiliac joint* OR sacro-iliac joint*) AND (Pseudarthrosis[MeSH] OR pseudarthros* 
OR pseudoarthros* OR pseudo-arthros* OR Arthrodesis[MeSH] OR arthrodes* OR tumor* OR tumour*OR cancer* 
OR neoplasm* OR carcinoma* OR Carcinoma[MeSH] OR Neoplasms[MeSH] OR Arthritis, Rheumatoid[MeSH] OR 
rheumatoid OR Spondylarthropathies[MeSH] OR Spondylarthropath*) AND (Denervation[MeSH] OR denervation* 
OR de-nervation* OR Radio Waves[MeSH] OR Pulsed Radiofrequency Treatment[MeSH] OR radiofrequency OR 
radio-frequency OR Electrocoagulation[MeSH] OR electrocoag* OR thermocoag* OR neurotom* OR neuroly*)) 
Total: 4 Hits 
 
